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Abstract
POTENTIAL MODIFICATIONS TO ENZYME REPLACEMENT THERAPY IN
ANDERSON-FABRY DISEASE
By
Mariam F. Meghdari

Advisor: David H. Calhoun, Ph.D.
Mutations in the GLA gene that encodes the lysosomal enzyme α-galactosidase A (αGal) result
in the sphingolipidoses named Fabry disease. This enzymatic defect is inherited as an X-linked
recessive disorder and is associated with a progressive deposition of glycosphingolipids,
including globotriaosylceramide (GB3), galabioasylceramide, and blood group B substance in
the cell. In affected males, and in some females, this leads to early death due to occlusive disease
of the heart, kidney, and brain. This disease is currently treated by infusions of αGal, prolonging
patients’ lives but producing antibodies against the enzyme reducing the treatment efficacy.
Treatment also causes numerous and sometimes life threatening infusion related adverse
reactions, including anaphylactic shock, and even death in rare occasions. Here we propose two
potential improvements to the current therapeutic practices which would allow for more effective
enzyme therapies. The first is constructing and analyzing potentially more active carboxylterminal deletions of αGal and the second focuses on targeting of αGal to the very high uptake
scavenger receptor (SR) for improved transport to the lysosome.
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Chapter 1 : Introduction
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Lysosomal storage diseases
Lysosomal storage diseases (LSDs) are a group of approximately 60 inherited metabolic
disorders caused by the absence or dysfunction of lysosomal enzymes (Figure 1-1).
LSD’s lead to a number of clinical manifestations due to the accumulation of intermediate
substrates of these enzymes in the lysosome. LSDs are individually classified as rare/orphan
diseases, combined they make up anywhere between 1 in 4000 to 1 in 13,000 live births
according to various published studies [31] with these numbers potentially being higher
according to recent with recent newborn screening studies [32, 33].

Fabry disease
Fabry disease is a disorder of glycosphingolipid metabolism due to deficient or absent lysosomal
of α-galactosidase A (αGal) activity (Figure 1-1) [34]. Numerous gene mutations of the protein
have been described. Patients with mutations leading to the total absence of αGal suffer the
classic form of Fabry disease, while those having missense mutations causing residual activity
(2% to 25%) suffer from the milder forms of the metabolic disorder [35]. In contrast to many
other LSDs, most patients remain clinically asymptomatic during the very first years of life. The
first symptoms include chronic pain, skin lesions, myocardial infarction, gastrointestinal
disorder, and vascular deterioration. Later in life, the complications associated with this disease
are often life threatening [36, 37].
Fabry disease is the second most common LSD after Gaucher disease, initially thought to have a
worldwide prevalence of approximately 1 in 40,000 to 1 in 117,000 live births for the classic
form of the disease [38]. However, current newborn screening initiatives have found an

2

Mariam Meghdari

unexpectedly high prevalence of the disease, as high as 1 in approximately 3,100 newborns in
Italy [39] and have identified a surprisingly high frequency of newborn males with Fabry
disease, approximately 1 in 1,500 in Taiwan [38]. These findings suggest that Fabry disease may
currently be under recognized, making the need for advancement in treatment more urgent.

Fabry Disease
αGal deficiency

Figure 1-1: Pathways for the breakdown of GM1(monosialotetrahexosylganglioside) the
"prototype" ganglioside, globoside and sphingomyeline to ceramide [40].
Pathway leading to Fabry disease highlighted in red.
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α-Galactosidase A (αGal)
The enzyme has a large amino-terminal catalytic domain, a small carboxyl-terminal domain, and
is present as a head-to-tail homodimer that hydrolyses the terminal alpha-galactosyl moieties
from glycolipids and glycoproteins [14]. The N-terminal domain is a classic (β/α)8 barrel, and the
C-terminal domain contains eight antiparallel β strands packed into a β sandwich (Figure 1-2)
[14]. The authors of this structure conclude that the carboxyl-terminal amino acids are most
likely not in contact with the catalytic site being “at least 45 Å from each active site and on the

Figure 1-2: Crystal structure of human αGal.
The α-galactosidase A polypeptide trace is shown with a rainbow from blue at the
N-terminus to red at the C-terminus. N-linked carbohydrates are shown as bonds,
and the galactose ligand is shown as spheres, marking the active site in the first
domain [14].
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opposite face of the molecule” and therefore most likely do not play a role in enzyme activity
[10].
Each monomer contains three N-linked carbohydrate sites (Asn-139, Asn-192 and Asn-215) and
five disulfide bonds. Elimination of any two glycosylation sites lead to an unstable enzyme and
premature degradation, while Asn-215 was shown to be essential for protein solubility [41].
There are a large number of known mutations (over half of the residues) in the GLA gene which
encode αGal causing Fabry disease. Most of these mutations lead to disruption of the
hydrophobic core of the protein making Fabry disease primarily a disease of protein-folding [42].

Available therapies
The FDA has approved treatment of Fabry disease through intravenous administration of
recombinant αGal known as enzyme replacement therapy (ERT) [3]. Two different forms of
ERT are available for the treatment of Fabry disease; both are administered by intravenous
infusion every other week and have been compared [3]. The first is genetically engineered in a
human cell line by gene activation (agalsidase alfa, Replagal®, Shire Human Genetic Therapies,
Inc., Cambridge, MA), the second produced in a Chinese hamster ovary cell line by recombinant
techniques (agalsidase beta, Fabrazyme ®, Genzyme Corporation, Cambridge, MA). The
recombinant enzymes contain mannose-6-phosphate (M6P) residues that are recognized by the
M6P receptor on the cell surface and incorporated into the cell [43]. However, the importance of
the M6P uptake system as the sole mechanism of uptake for αGal has recently been questioned
[15]. Uptake of αGal is mainly mediated by the high molecular weight endocytic receptor
megalin in proximal tubule cells [44] . The sortilin receptor has also been identified as an αGal
binding protein important in human glomerular endothelial cells [15]. The endocytic receptors
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M6P, sortilin, and megalin have been identified to play a role in αGal cellular internalization in
podocytes [45].
The clinical efficacy of ERT for Fabry disease has been shown through several clinical trials [3,
46-49]. Therapy was initially undertaken for males with the classic form of the disease (no
detectable αGal activity) [36, 50, 51], but is now also underway for symptomatic heterozygous
females [43, 52]. Treatment is also under consideration for adults and children with atypical (low
levels of enzyme) Fabry disease. More than 80% of Fabry patients treated with agalsidase-beta
and 56 % treated with agalsidase-alfa developed an immune response [50, 51]. The antibodies
are primarily of the IgG class, in addition, a fraction of the antibodies appear to exhibit
neutralizing properties, which has been associated with an increase in urinary
globotriaosylceramide (GB3) levels due to the uptake of immune-enzyme complexes by
granulocytes in the bloodstream and macrophages in the tissues [53-55].
Fabry disease patients with adverse reactions to the infusions are currently treated with
antihistamines and antipyretics and the initial immune response is typically manageable [56]. It
can be anticipated however, that life-long treatment required for these patients will lead to
unacceptable levels of neutralizing antibodies. The drug cost of ERT is very high, running
between $75,000 and $350,000 per patient-year, depending on the body weight of the patient as
opposed to a generally accepted threshold for a new drug of $50,000–$150,000 [57]. The
limitations of current approaches for ERT for Fabry disease and the need for improved
techniques have been discussed [58, 59]. In addition, the effects of gene therapy [60-67] and
pharmacological chaperones [68] are under investigation for the treatment of Fabry disease.
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The recombinant enzymes prescribed for ERT are produced in mammalian cells (human or CHO
cells). Producing adequate amounts of protein for ERT from mammalian cells is expensive.
Mammalian cell culture is highly susceptible to viral infections, compromising the constant
supply needed by patients. In 2009, a contamination in one of Genzyme’s plants forced a halt to
the manufacturing of Fabrazyme, used to treat for Fabry patients, and Imiglucerase
(Cerezyme®), for Gaucher patients. This caused a shortage in the United States and lasted until
2012, when the production was moved to a new plant [69]. These cells are used in part because
the glycan structure is similar to that of native enzyme, allowing for the necessary M6P exposure
and decreasing potential antigen production [43].
Alternative expression systems have been used for the production of αGal. Tobacco cell cultures
[70] and the moss (Physcomitrella patens) [1] have both been successfully used to produce
active forms of human αGal. Both of these systems have been engineered to perform human-like
glycosylation. Recombinant αGal has also been produced in a modified yeast strains where
Saccharomyces cerevisiae was manipulated to synthesize glycoprotein that lacks the outer chain
of N-glycan, a structure that is specific to yeast but not humans [71]. αGal purified by that group
was introduced into Fabry patient fibroblasts and a Fabry mouse model and successfully
hydrolyzed accumulating substrates [71]. This study supports the use of yeast as a host for
recombinant αGal production for ERT. These alternative systems could help lower the cost of
treatments, increase manufacturing safety, and improve availability of ERT therapeutic options
for patients decreasing the probability of shortages in the future.
In this work, we use the methylotrophic yeast Pichia pastoris. P. pastoris is the most highly
developed of a small group of alternative yeast species chosen for their advantages over S.
cerevisiae as expression hosts. This is due in part to the existence of well-established
7
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fermentation methods and the presence of a tightly regulated methanol-inducible promoter
PAOX1. Alcohol oxidase (AOX) expression is undetectable in cells cultured on carbon sources
such as glycerol, but constitutes up to 30% of total soluble protein in methanol-grown cells.
Therefore, genes under the control of the PAOX1 promoter can be maintained in an expression-off
mode on a non-methanolic carbon source to minimize selection for non-expressing mutant
strains during cell growth, and then efficiently switched on by shifting to methanol. We propose
two new and innovative approaches allowing for more effective enzyme therapies and potentially
circumventing adverse reactions.

Scope of work
Aim 1: Carboxyl-Terminal Deletions of αGal. Based on a previous report [2] indicating a
possible correlation between C-terminal deletions of human αGal and enzyme activity; the first
major goal of this research was to explore the effects of C-terminal deletions of the human αGal
on enzyme activity. According to work done by Miyamura’s group, carboxyl-terminal deletions
of the human αGal protein led to an increase of activity using a transient expression system [2].
This data was semi-quantitative and relied on comparison of the amounts of RNA present in
northern blots of mRNA for αGal compared to β-actin (Figure 1-3). We constructed a set of even
(2, 4, 6, 8, 10 amino acids) carboxyl-terminal deletion mutants, and characterized the Km, and
Vmax of these mutants.
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Figure 1-3: Relative enzyme activity of C-terminal deletions of human αGal [2].
A) Mutant cDNAs with premature stop codons yielding deletions were obtained by sitedirected mutagenesis. Amino acid sequence of the C-terminal residues are shown in the
right. αGal activities obtained from cell lysates in transfections with these plasmids are
shown in the left. αGal activity was adjusted by subtraction of activity seen after mocktransfection, and normalization by the ratio of the αGal mRNA to the β-actin mRNA in the
Northern blot. Values are shown as % control (WT=100), representing mean for n=2-3. B)
Northern blot, representative autoradiogram is shown.
Aim 2: Targeting of αGal to mannose and scavenger receptors of endothelial cells. The
scavenger receptors (SRs) bind acetylated or oxidized low-density lipoprotein and
macromolecules with negative charge, leading to subsequent degradation in the lysosome [72].
We hypothesized that αGal transported by way of functionalized liposomes or coupled to
scavenger ligands would be delivered to lysosomes to degrade accumulated substrates in Fabry
disease patients. We also hypothesized that mannose terminated αGal expressed in yeast would
target the mannose receptors (MR) present on endothelial cells improving uptake in these cells.
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These strategies have the potential to significantly reduce the number of infusions needed for the
desired therapeutic effect. Currently there are more than 50 LSDs [50, 73] including Fabry
disease that could potentially be treated through ERTs, making the possible contribution of this
work to the field vast.
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Chapter 2 : Carboxyl-Terminal Truncations Alter the
Activity of the Human α-Galactosidase A
Mariam Meghdari1, Nicholas Gao1, Abass Abdullahi2, Erin Stokes1, and David H. Calhoun1

1. Chemistry Dept., City College of New York, ChemistryDepartment, 160ConventAve, NewYork,
NY 10031, USA
2. Biology & Medical Lab Technology, Bronx Community College, Bronx, NY, USA

Published in PlosOne: February 26, 2015,
http://dx.doi.org/10.1371/journal.pone.0118341
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Abstract
Fabry disease is an X-linked inborn error of glycolipid metabolism caused by deficiency of the
human lysosomal enzyme, αGal, leading to strokes, myocardial infarctions, and terminal renal
failure, often leading to death in the fourth or fifth decade of life. The enzyme is responsible for
the hydrolysis of terminal α-galactoside linkages in various glycolipids. ERT has been approved
for the treatment of Fabry disease, but adverse reactions, including immune reactions, make it
desirable to generate improved methods for ERT. One approach to circumvent these adverse
reactions is the development of derivatives of the enzyme with more activity per mg. It was
previously reported that carboxyl-terminal deletions of 2 to 10 amino acids led to increased
activity of about 2 to 6-fold. However, this data was qualitative or semi-quantitative and relied
on comparison of the amounts of mRNA present in Northern blots with αGal enzyme activity
using a transient expression system in COS-1 cells. Here we follow up on this report by
constructing and purifying mutant enzymes with deletions of 2, 4, 6, 8, and 10 C-terminal amino
acids (Δ2, Δ4, Δ6, Δ8, Δ10) for unambiguous quantitative enzyme assays. The results reported
here show that the kcat/Km approximately doubles with deletions of 2, 4, 6 and 10 amino acids
(0.8 to 1.7-fold effect) while a deletion of 8 amino acids decreases the kcat/Km (7.2-fold effect).
These results indicate that the mutated enzymes with increased activity constructed here would
be expected to have a greater therapeutic effect on a per mg basis, and could therefore reduce the
likelihood of adverse infusion related reactions in Fabry patients receiving ERT treatment. These
results also illustrate the principle that in vitro mutagenesis can be used to generate αGal
derivatives with improved enzyme activity.
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Introduction
Mutations in the αGal gene result in the sphingolipidosis named Fabry disease [74]. The
enzymatic defect is inherited as an X-linked disorder and is associated with a progressive
deposition of the glycosphingolipids, including globotriaosylceramide, galabioasylceramide, and
blood group B substance. In affected males, this leads to early death due to occlusive disease of
the heart, kidney, and brain.
De Duve [75] first suggested that ERT might be a successful approach to the treatment of
lysosomal storage defects such as Gaucher’s and Fabry disease. For Gaucher’s disease, ERT
produced unequivocal clinical responses [76, 77] that were subsequently confirmed by others
[78-80]. Classical Fabry disease patients lack detectable levels of αGal [74] so it should not be
surprising that more than 80% of Fabry patients treated with agalsidase-beta [50] and more than
50% treated with agalsidase-alfa [51] developed an immune response. The antibodies produced
are primarily of the IgG class and a fraction of the antibodies appear to exhibit neutralizing
properties. These antibodies have been associated with an increase in urinary
globotriaosylceramide levels due to the uptake of immune-enzyme complexes by granulocytes in
the bloodstream and macrophages in the tissues [53-55].
ERT for Fabry disease patients was initially undertaken for males with the classic form of the
disease (no detectable αGal activity) in a variety of clinical trials [34, 36, 37, 50, 51, 81], but
therapy is now also underway for heterozygous females with Fabry disease [43, 46, 82] and is
under consideration for children [48, 83, 84] and adults with atypical (low levels of enzyme)
Fabry disease [85]. The two products used for ERT in Fabry disease patients have been
compared [3]. The pattern of glycosylation on αGal has been analyzed [86] and its importance
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for activity [41] and uptake by cells has been established [71, 87]. The limitations of current
approaches for ERT for Fabry disease and the need for improved techniques have been discussed
[55, 88, 89]. Efforts for gene therapy for Fabry disease are underway [60-65, 67, 90] and
molecular chaperones are under investigation for specific alleles[91-93]. Substrate reduction
therapy as an augmentation to ERT has been evaluated [94]. There are several reviews on the
general topic of ERT for lysosomal storage diseases [95-99].
Expression of the human αGal has been reported in Escherichia coli [12], baculovirus [8, 9]
Chinese hamster ovary cells [100] and human foreskin fibroblasts [101].The highest levels of
heterologous αGal expression was observed in P. pastoris [7]. Recombinant αGal has also been
produced in a modified strain of S. cerevisiae that synthesized glycoprotein lacking the outer
chain of N-glycan, a structure that is specific to yeast but not humans[71, 102]. When this αGal
was introduced into Fabry patient fibroblasts or a Fabry mouse model, there was hydrolysis of
accumulated substrates [71, 102].
The methylotrophic yeast P. pastoris is the most highly developed of a small group of alternative
yeast species chosen for their advantages over S. cerevisiae as expression hosts [103, 104]. Two
attributes critical in its selection are the existence of well-established fermentation methods and
the presence of the tightly regulated methanol-inducible promoter. AOX expression is
undetectable by enzyme assay or mRNA production in cells cultured on carbon sources such as
glycerol, but constitutes up to 30% of total soluble protein in methanol-grown cells.
Heterologous genes under the control of the PAOX1 promoter can be maintained in an expressionoff mode on a non-methanolic carbon source in order to minimize expression of potentially toxic
heterologous proteins during cell growth. The P. pastoris expression system has now been
successfully used to produce a number of heterologous proteins at commercially useful
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concentrations [105].
Lysosomal enzymes such as αGal are glycoproteins that are modified in the Golgi to contain N
or O-linked carbohydrate structures [106]. The human αGal is glycosylated at Asp residues 139,
193, and 215 [41] with branched carbohydrate structures that vary in composition and sequence
depending upon the host species and tissue type [86]. For example, the enzyme purified from
humans contains variable amounts (5–15%) of asparagine linked complex and high mannose
oligosaccharide chains [74]. Consequently, multiple forms are present in SDS gels and in
isoelectric focusing experiments that correspond to the plasma and various tissue forms. The
recombinant human αGal preparations used therapeutically are produced in human and CHO
cells and these have distinct glycosylation patterns and differ in levels of sialic acid and M6P [3].
The recombinant αGal produced in insect cells [8, 9] and in P. pastoris [7] contain variable
levels of mostly complex and high mannose side chains, respectively. Glycoproteins produced in
P. pastoris typically contain from 6 to 14 mannose units (Man6GlcNac2 to Man14GlcNac2) that
sometimes produces a Gaussian-like distribution of oligomannosides that may center near
Man12GlcNac2 to Man13GlcNac2 [107].
These carbohydrate moieties serve a structural and functional role. For example, it has been
demonstrated that glycosylation, particularly at Asn-215, is required for enzyme solubility [41].
Also, uptake of the enzyme by cells in vivo is affected by terminal M6P residues on the enzyme
[87], and the 10–12 sialic acid residues on the plasma form of the enzyme accounts for the
prolonged circulatory half-life of the enzyme compared to the tissue form with only one or two
sialic acid residues [25]. The identification of these multiple forms as derivatives of the same
protein in purified enzyme preparations can conveniently be monitored by treatment with
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specific N-glycosidases or by Western blots.
Fabry disease patients with adverse reactions to the infusions are currently treated with
antihistamines and antipyretics and the initial immune response has been manageable to date [56,
108], but it can be anticipated that life-long treatment required for these patients will lead to
unacceptable levels of neutralizing antibodies. In this context, it is reasonable to devise
approaches to circumvent these adverse reactions and the development of derivatives of the
enzyme with more activity per mg is a logical approach. Miyamura and coworkers [2] reported
that carboxyl-terminal deletions of 2 to 10 amino acids of αGal led to an increase in activity of
about 4 to 6-fold as compared to wild type (WT). However, this data was qualitative or semiquantitative. αGal activity was measured in cell lysates during transient infection of COS-1 cells
using the artificial substrate MUG with a mock-transfection being used as a blank background
subtraction. These results were then normalized by using the ratio of αGal to actin mRNA
present in Northern blots. Here we use a P. pastoris expression system for the construction and
purification of mutant enzymes with C-terminal deletions. The quantitative results reported here
with purified enzymes reveal that C-terminal deletions results in an increase (Δ2, Δ4, Δ6, and
Δ10) or decrease (Δ8) in enzyme activity.

Materials and Methods
Cell strains and plasmids
The P. pastoris host strain X-33 (No. K1740-01), E. coli strains TOP10 (No. C4040-50) and
1

TOP10F′ (No. C665-11), plasmid pPICZαA (No. K1740-01), and TOPO XL PCR cloning kit
(No. K4700-10) were purchased from Invitrogen.
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Bioreactor expression of recombinant αGal in P. pastoris
High-cell-density fermentation was carried out as previously described [7] with a modified
growth medium utilizing non-precipitating sodium hexametaphosphate as a phosphate source
[109]and modified for a 7 L Applikon bioreactor. Fermentation medium of 3.5 L (0.93 g/l
CaSO4, 18.2 g/l K2SO4, 14.9 g/l MgSO4.7 H2O, 9 g/l (NH4)2SO4, 40.0 g/l glycerol) was
autoclaved at 121°C for 20 min in the vessel. After cooling to room temperature, filter sterilized
sodium hexametaphosphate (25 g/l of fermentation basal salt medium dissolved in 500 ml of
deionized water) and 0.435% PTM1 trace elements (CuSO4.5 H2O 6.0 g, NaI 0.08 g, MgSO4.
H2O 3.0 g, Na2MoO4.2 H2O 0.2 g, H3BO3 0.02 g, CoCl2 0.5 g, ZnCl2 20.0 g, FeSO4.7 H2O
65.0 g, biotin 0.2 g, 5.0 ml H2SO4 per liter) were added to complete the fermentation medium.
The pH was adjusted to 6.0 using ammonium hydroxide (28%).
Four frozen MGY cultures of 4 ml each were used to inoculate four 100 ml MGY cultures in 1liter baffled flasks and grown at 250 rpm and 30°C until the OD600 reached 2 to 6. The
cultivation was divided into three phases, the glycerol batch, glycerol-fed batch, and methanol
fed batch. The glycerol batch phase was initiated with 400 ml of inoculum shake-flask culture
added to 4 L of the fermentation medium containing 4% glycerol and an initial value of 100%
dissolved oxygen until a spike was observed indicating complete consumption of glycerol. Next,
the glycerol-fed batch phase was initiated and a 50% w/v glycerol feed rate of 18.15 ml/h/ liter
initial fermentation volume and maintained until a cell yield of 180 to 220 g/liter wet cells was
achieved. At this point the glycerol feed was terminated manually and a methanol-fed batch
phase was initiated by starting a 100% methanol feed containing 12 ml PTM1 trace salts per
liter. Methanol was initially fed at 3.6 ml/h/liter of initial fermentation volume, then increased to
7.3 ml/h/liter and finally increased to 10.9 ml/h/liter of initial fermentation volume for the
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remainder of the fermentation. Dissolved oxygen spikes were used during the glycerol fed batch
phase and methanol-fed batch phase and to monitor substrate levels. A dissolved oxygen level of
40%, pH of 6, and temperature of 25 °C were maintained by an ADI 1030 regulator. Sampling
was performed at the end of each phase and at least twice daily and analyzed for cell wet weight
and increased αGal activity over time. Cultivation was terminated once a plateau in αGal activity
was observed.
Construction of strains
Plasmid pMS118 [12] contains the αGal cDNA cloned as an EcoRI fragment to the EcoRI site of
plasmid pUC9. PCR primers (Figure. 2-1, 2-2) were used with plasmid pMS118 DNA and the
PCR system (Roche, No. 11732641001) according to the vendor’s instructions. This generated
cDNAs with a 5¢ extension containing an XhoI site, Kex2 and Ste13 yeast signal cleavage sites, a
3¢ end with an XbaI site, and a deletion of C-terminal amino acids to generate Δ2 to Δ10 mutants
(Figure 2-1, 2-2). The PCR products were ligated to pCR-XL-TOPO to generate Δ2 to Δ10
plasmids (Table 2-1). These plasmids were used for electroporation [7] into E. coli strain TOP10
or TOP10F¢ (Table 2-1).
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Figure 2-1: Introduction of a C-terminal deletion of 2 amino acids into αGal.
The strategy shown here for the Δ2 mutant was used to generate all five deletion mutations (Figure 22). Plasmid pMS118 [12] contains the αGal cDNA cloned as an EcoRI fragment to the EcoRI site of
plasmid pUC9. Primers AAF and AARD2 (Figure 2-2) were used as PCR primers for plasmid pMS118
DNA to generate cDNAs with a 5′ extension containing an XhoI site, Kex2 and Ste13 yeast signal
cleavage sites, a 3′ end with an introduced XbaI site, and a deletion of C-terminal amino acids to
generate the Δ2 mutant. Primer AAF anneals to the cDNA at the sequences encoding the N-terminal
sequences of αGal and primer AARD2 anneals to the C-terminal sequences of αGal. Primer AARD2
anneals 12 nucleotides from the 3′ end of the cDNA and introduces a stop codon (UAA) after the
aspartate codon three amino acids from the C-terminal end of the coding sequences of αGal resulting in
a deletion of the two C-terminal amino acids (Leu-Leu) of the human enzyme (right panel). Cloning to
the XhoI and XbaI sites of plasmid pPICZαA generates a protein fusion with the yeast signal peptide
coding sequences in the vector. This signal peptide is removed by the Kex2 and Ste13 yeast signal
peptidases through cleavage immediately upstream of the leucine corresponding the first amino acid of
the mature form of αGal (left panel). This strategy was generalized to create the other deletion mutants
using the primers in (Figure 2-2). In the left panel, the N-terminal peptide LDNGLAR was identified in
mass spectrometric analysis while EALDNGLAR was not (Figure 2-5).
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Figure 2-2: Primers and αGal cDNA used to generate Δ 2, Δ 4, Δ 6, Δ 8 and Δ 10 mutant cDNAs.
DNA primers AAF, AARD2, AARD4, AARD6, AARD8 and AARD10 corresponding to the Δ2, Δ4, Δ6, Δ8 and Δ10 mutants were
annealed to the cDNA of mature αGal contained within pMS118 to generate 3′ end truncated PCR products for carboxy-terminal
deleted enzymes. Primer AAF and primers AARD2 to AARD10 (indicated above) were annealed to the 5′ and 3′ ends of the cDNA,
respectively. Primer AAF contains an XhoI site (indicated above) and partially encodes for a yeast signal peptide (see Figure 2-1) to
produce a fusion protein targeted for secretion from P. pastoris. Primers AARD2 to AARD10 were used to introduce an XbaI site
(indicated above) and a premature UAA stop codon via an antisense ATT triplet immediately downstream of nucleotides
complementary to αGal (bold font) to produce cDNAs encoding for Δ2, Δ4, Δ6, Δ8, Δ10 mutants. The boxed LDNGLAR and
SHINPTGTVLLQLENTMQM protein sequences (indicated above) are peptide fragments that were identified through mass
spectrometry of the Δ6 mutant (Figure 2-5).
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Table 2-1: Starins and Plasmids

Strain

Species

Plasmid

CC878

E. coli

pCC248

CC892

E. coli

pCC262

CC970

E. coli

pCC278

CC973

E. coli

pCC281

CC983
CC990

E. coli
E. coli

pCC291
pCC298

CC993

E. coli

pCC301

CC994

E. coli

pCC302

CC995
CC997
PC626
PC897
PC958
PC960
PC971
PC973
TOP10
TOP10F′
X-33

E. coli
E. coli
P. pastoris
P. pastoris
P. pastoris
P. pastoris
P. pastoris
P. pastoris
E. coli
E. coli
P. pastoris

pCC303
pCC305
pCC106
pCC262
pCC291
pCC298
pCC303
pCC305
None
None
None

Description
pCR-XL-TOPO derivative plasmid a modified cDNA using primers AAF
and AARD4 to generate C-terminal deletion of 4 amino acids (Δ4)
pPICZαA derivative plasmid with Δ4 cDNA insert
pCR-XL-TOPO derivative plasmid a modified cDNA using primers AAF
and AARD6 to generate C-terminal deletion of 6 amino acids (Δ6)
pCR-XL-TOPO derivative plasmid a modified cDNA using primers AAF
and AARD10 to generate C-terminal deletion of 10 amino acids (Δ10)
pPICZαA derivative plasmid with Δ6 cDNA insert
pPICZαA derivative plasmid with Δ10 cDNA insert
pCR-XL-TOPO derivative plasmid a modified cDNA using primers AAF
and AARD2 to generate C-terminal deletion of 2 amino acids (Δ2)
pCR-XL-TOPO derivative plasmid a modified cDNA using primers AAF
and AARD8 to generate C-terminal deletion of 8 amino acids (Δ8)
pPICZαA derivative plasmid with Δ2 cDNA insert
pPICZαA derivative plasmid with Δ8 cDNA insert
Integrated pPICZαA derivative with WT cDNA insert [7]
Integrated pPICZαA derivative with Δ4 cDNA insert
Integrated pPICZαA derivative with Δ6 cDNA insert
Integrated pPICZαA derivative with Δ10 cDNA insert
Integrated pPICZαA derivative with Δ2 cDNA insert
Integrated pPICZαA derivative with Δ8 cDNA insert
E. coli host for modified Δ2, Δ6, Δ8, Δ10 cDNA plasmids
E. coli host for pCC106 and modified Δ4 cDNA plasmid
Expression host for αGal expression

DNA sequence analysis using the universal M13 primers (Table 2-2) confirmed the expected
insert for these pCR-XL-TOPO derivatives. The modified cDNAs were excised from pCRXLTOPO plasmids using XhoI and XbaI endonucleases and ligated into expression plasmid
pPICZαA treated with the same two restriction enzymes to generate expression plasmids (Table
2-1) that were subsequently used for electroporation [7] into strain TOP10 or TOP10F′ (Table 21). The nucleotide sequence of mutant cDNAs in pPICZαA derivatives was analyzed (Genewiz)
using 5′ AOX, 3′ AOX and α-factor sequencing primers (Table 2-2). These pPICZαA
derivatives were used for electroporation of P. pastoris strain X-33 to generate yeast expression
strains (Table 2-1).
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Table 2-2: Primers Used for DNA Sequence Analysis.
Primer

Sequence

Function

5′ AOX

5′ GACTGGTTCCAATTGACAAGC
3′

DNA sequencing primer for pPICZαA

3′ AOX

5′ GCAAATGGCATTCTGACATCC
3′

DNA sequencing primer for pPICZαA

α-factor

5′ TACTATTGCCAGCATTGCTGC 3′ DNA sequencing primer for pPICZαA

M13:
forward

5′ GTAAAACGACGGCCAG 3′

M13: reverse 5′ CAGGAAACAGCTATGAC 3′

DNA sequencing primer for pCR-XLTOPO
DNA sequencing primer for pCR-XLTOPO

Note. Primers were HPLC purified, 50 nmoles from Invitrogen
Purification of αGal using double affinity chromatography
Purification was as described [7, 110] with minor modifications (below). Bioreactor supernatant
was passed through a 0.2 µm hollow fiber filter (Spectrum Labs, No. M22M-300-01N) and
subjected to diafiltration using a 50 kDa pore size hollow fiber filter (Spectrum Labs, No. M25S300-01N) against wash buffer (0.1 M sodium acetate buffer, pH 6.0, 0.1 M NaCl, 1 mM MgCl2,
1 mM CaCl2, 1 mM MnCl2). The resulting supernatant was applied to a Con A Sepharose 4B
(GE Healthcare No. 17-0440-01) column, pre-equilibrated with wash buffer, and washed with 5
column volumes of wash buffer. It was observed that near-saturating sugar eluent concentrations
do not improve glycoprotein recovery as compared to lower concentrations and that elution
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phase pauses improve recovery [111]. In accordance with these findings, elution of αGal was
carried out using modified elution buffer I (0.5 M methyl-α-D-mannopyranoside, 0.25 M methylα-D-glucopyranoside in wash buffer) over 1.5 column volume blocks separated by 12-hour
interval soaks. Elution was discontinued when the absorbance at 280 nm and enzyme assays
showed negligible presence of protein and αGal activity. No substantial difference in recovered
enzyme was observed between purifications carried out with modified elution buffer I versus
sugar saturated elution buffer I (data not shown). The Con A pool was subjected to diafiltration
using a 50 kDa pore size hollow fiber filter (Spectrum Labs, No. M25S-30001N) against binding
buffer (25 mM citrate-phosphate buffer, pH 4.8 containing 0.1 M NaCl).
The Con A pool was applied to an immobilized-D-galactose gel column (Thio-Gal, Pierce No.
20372) pre-equilibrated with binding buffer. The column was washed with 5 column volumes of
binding buffer and αGal was eluted with elution buffer II (25 mM citrate-phosphate buffer, pH
5.5, 0.1 M NaCl, 0.1 M D-galactose) over 1.5 column volume blocks separated by 12 hour soaks.
Fractions were assayed for enzyme activity and protein concentration and a peak tube with high
specific activity was chosen as the sample to be used in a substrate saturation curve.
Electrophoresis analysis
Samples (8 µg) were mixed with an equal volume of reducing sample buffer (Bio-Rad Laemmli
sample buffer with 5% β-mercaptoethanol) and heated for 5 minutes at 95 °C before loading on a
Mini-Protean TGX Precast Gel 4–20% (w/v) (Bio-Rad No. 456-1094). Bands were visualized by
Coomassie blue staining via the modified Fairbanks protocol [112].
Western blot analysis
Western blot analysis was performed using an anti-αGal polyclonal antibody produced in
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chicken (Pierce/ThermoSci #PA1-9528) and horseradish peroxidase-conjugated anti-Chicken
IgY antibody (Sigma #A9046). After SDS-PAGE (2 µg of samples loaded), the gel was
incubated with a nitrocellulose membrane (Whatman, No. 10402594) for 15 minutes at room
temperature in Transfer Buffer (48 mM Tris, 39 mM glycine, 20% MeOH, pH 9.2) and the
proteins were then transferred to the nitrocellulose membrane using a Bio-Rad Trans Blot SD
Semi-Dry Transfer Cell. The membrane was blocked with 8% (w/v) non-fat dried milk in PBST
[10 mM Na2HPO4, 1.8 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl and 0.2% Tween 20 (pH
7.4)] at room temperature for 20 minutes. The membrane was then treated with primary antibody
diluted in a milk/blot solution [1% (w/v) non-fat dried PBST] for 2 h at room temperature with
mild shaking. After rinsing with PBST solution, the membrane was treated for 1 h at room
temperature with secondary antibody diluted in the milk/blot solution. Protein bands were
visualized on Kodak BioMax XAR film (VWR #lB1651454) with a Konica SRX-101A
processor.
Enzyme and protein assays
Activity of αGal was assayed using the synthetic substrate, 4-methylumbelliferyl-α-Dgalactopyranoside (MUG) as described [7] with modifications to a microtiter plate format
(below). Enzyme activity is measured in units/ml where one unit is defined as the amount of
enzyme required to convert 1 nmole of MUG to 4-methylumbelliferone in one hour at 37 °C. An
aliquot of 3 µl was added to 27 µl of enzyme assay buffer (5 mM MUG in 40 mM sodium
acetate buffer, pH 4.5). This mixture was incubated at 37 °C and 10 µl aliquots were taken at two
time points and added to 290 µl of 0.1 M diethylamine in a microtiter plate to stop the reaction.
Typically, time points were chosen as 1–4 minutes and values that were proportional to time
were considered valid. The fluorescence of each sample was measured at an excitation
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wavelength of 365 nm and an emission wavelength of 450 nm using a Tecan Infinite F200
microtiter plate reader. A standard curve of 10 µl of 0 – 0.5 nmol 4-methylumbelliferone
dissolved in MeOH in 290 µl of 0.1 M diethylamine was used to quantitate MUG cleavage at
specific time intervals. Analysis of the effects of MeOH indicated no effect on the 4methylumbelliferone standard curve.
For samples containing higher protein concentrations, the BioRad DC Protein Assay (No. 5000116) with a standard curve of (0.2 – 1.5) mg/ml was used according to the manufacturer’s
specifications. For dilute samples of purified αGal, a more sensitive fluorescence-based
fluorescamine assay [113] with a standard curve containing lower protein concentrations of (4.0–
160) µg/ml was used. Briefly, 150 µl of 0.05 M sodium phosphate buffer and 50 µl of 1.08 mM
fluorescamine dissolved in acetone were added to an aliquot of 50 µl of the sample and
standards, mixed and incubated for 12 minutes. The fluorescence of each sample was measured
at an excitation wavelength of 400 nm and an emission wavelength of 460 nm. Bovine serum
albumin (Bio-Rad No. 500-0112) was used as the standard in both assays. Absorbance and
fluorescence measurements were conducted on a Tecan Infinite F200 microplate reader using 96well plates.
Mass spectrometry of a purified mutant enzyme
The Δ6 mutant was selected for mass spectrometry analysis conducted at the Rockefeller
University Proteomics Resource Center in collaboration with M.T. Mark. SDS-PAGE gel slices
were washed, de-stained, reduced using 10 mM dithiothreitol, alkylated using 100 mM
iodoacetamide, and digested using trypsin. Peptides were then extracted from the gel two times,
dried, and re-suspended in a 5% acetonitrile and 2% formic acid mixture. One third of each
sample was loaded onto a C18 PepMap1000 micro-precolumn (300 µm I.D., 5 mm length, 5 µm
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beads, Thermo Scientific) at a flow-rate of 5 µl/min, and subsequently onto an analytical C18
column (75 µm I.D., 3 µm beads, Nikkyo Technos Co.) at a flow rate of 300 nl/min. The gradient
was 40 min long in the range 5 to 45% B (buffer A was 0.1% formic acid in water, and buffer B
was 0.1% formic acid in acetonitrile). Eluted peptides were applied by electrospray directly into
the LTQ-Orbitrap XL mass spectrometer from Thermo Scientific, operating in a 300 to 1800 m/z
mass range. Tandem mass spectrometry was performed by collision induced dissociation using
nitrogen as a collision gas. The resulting spectra were analyzed using Mascot and Proteome
Discoverer 1.3 (Thermo Scientific) to identify the peptides in the sample.
Thermostability and pH optimum of WT and mutant αGal
Purified enzyme samples were diluted in 25 mM citrate-phosphate buffer, pH 5.5, 0.1 M NaCl,
0.01 M D-galactose. Samples of 50 µl were incubated in triplicate at 50 °C, 30 °C and 40 °C.
Aliquots of 3 µl were removed for enzyme assays every 15 minutes for two hours. Samples were
assayed in 0.02 M citrate buffer, pH 3.0-pH 6.5, containing 2 mM MUG.
Characterization of kinetic properties
Substrate saturation curves for αGal have been reported using MUG at concentrations up to 2
mM, 5 mM, and 10 mM (in the presence of 0.1% BSA and 0.67% EtOH [3]). We noted that
under our experimental conditions MUG is fully soluble at 2 mM, partially soluble at 5 mM, and
chemically oversaturated at higher concentrations. Other investigators reported the use of
sonication or detergent treatment to increase the solubility of MUG (e.g., [26]) but we avoided
this approach in order to avoid potential artifacts due to the use of these techniques. Substrate
saturation curves using 2 mM and 5 mM MUG as the highest concentrations were carried out
and the kinetic parameters for αGal were calculated separately obtaining similar values. The
values reported here (Table 2-3A) were obtained using a substrate saturation curve of 0.3 to 2
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mM MUG since this is the highest concentration that is fully soluble under our experimental
Table 2-3: Values of Km, Vmax, kcat and and the specificity constant (kcat/Km) for WT and C-Terminal
Deletion Mutants of αGal.

conditions. The Km and Vmax values were calculated using Lineweaver-Burk and non-linear
regression through the program Sigma-Plot (Systat Software, San Jose, CA).
Kinetic parameters were also determined using the colorimetric substrate, para-nitrophenyl-α-Dgalactopyranoside (PNPαGal) (Table 2-3B). [114] Purified enzymes were diluted to
approximately 20,000 units/mL as determined by fluorescent MUG assay. These diluted samples
were then added at a proportion of 1:9 citrate-phosphate buffer (0.1 M) containing 7 - 50 mM
PNPαGal. Aliquots of 20 µl of the enzymatic reaction were removed at 15 minute intervals to
terminate the reaction over the course of an hour and added to 320 µl of borate buffer (pH 9.8) in
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a microplate. Product formation was monitored by absorbance at 400 nm. Linear reaction
velocities were observed for all measurements. A standard curve of 0–150 µM p-nitrophenylate
in borate buffer (pH 9.8) [115] was used to quantitate product formation. Km and Vmax
parameters were determined through non-linear regression using Sigma-Plot (Systat Software,
San Jose, CA).
Protein structure analysis
The crystal structure of αGal (PDB 1R47) was viewed and analyzed in PyMOL (Delano
Scientific). The MSLDKLL and QMSLKDLL peptides corresponding to the last 7 or 8 Cterminal amino acids of αGal were built in PyRosetta [116] and visualized in PyMOL [117].
Interatomic distances were measured using the PyMOL wizard distance command.
A homology model of the coffee bean α-galactosidase was generated on the Phyre2 server [118].
The primary sequence of coffee bean α-galactosidase (GenBank No. AAA33022.1) was set as
the query. The crystal structure of rice α-galactosidase (73% sequence identity to coffee αgalactosidase, PDB# 1UAS) was set as the template. Superposition of the coffee homolog and
human crystal structure of αGal (PDB# 1R47) was conducted in PyMOL [117]. Primary
sequence alignments were carried out in ClustalOmega (EMBL-EBI).

Results
Purification of WT and mutant αGal
The WT and mutant enzymes were obtained from a 7 L bioreactor and purified (Table 24, Figure 2-3) using Con A and Thio-Gal tandem affinity chromatography. This two-column
purification is simpler and faster than our previous purification methods that used three [9] or
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four [7, 8] columns and the yield, degree of purity, and final specific activities were similar for
all three methods.
Table 2-4: Purification Table for WT αGal Expressed in P. pastoris.

The non-glycosylated form of αGal (41.8 kDa) is isolated from cells as multiple glycosylated
species with a predominant band of about 50 kDa and multiple higher molecular weight forms
that differ in extent of glycosylation (Figure 2-3; See Introduction). We have previously
demonstrated that high molecular weight glycoforms produced in insect cells and P. pastoris can
be identified as derivatives of αGal rather than contaminants and these glycoforms are converted
to a single band on SDS gels of about 41.8 kDa with endoglycosidase treatment [7-9], In this
report we also use a Western blot (Figure 2-4) to confirm that the high molecular weight forms
seen on SDS gels for the WT and deletion mutants are all glycoforms of αGal. In some cases,
lower molecular weight species present in purified enzyme preparations can be identified as αGal
fragments in Western blots (e.g., Figure 2-4, lane 2). We quantitated the distribution of
glycoforms in (Figure 2-3, S1 Fig, online supplement) and there is no obvious correlation
between the glycosylation pattern and catalytic activity. It is well established that glycosylation
affects enzyme stability and enzyme uptake (above) but to our knowledge there is no evidence
that the glycosylation pattern affects the catalytic properties of this enzyme.
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Figure 2-3: SDS-PAGE for purification of αGal.
Purified samples were run on a 4–20% polyacrylamide gel, under reducing conditions, and stained
with Coomassie Brilliant Blue. The contents of the lanes are as follows: molecular weight marker
(lane 1 and 8), WT(PC626) (lane 2), Δ2 (PC995) (lane 3), Δ4 (PC897) (lane 4), Δ6 (PC958) (lane
5), Δ8 (PC973) (lane 6), Δ10 (PC960) (lane 7). The minor bands present in the purified fraction are
consistent with high molecular weight glycoforms seen previously when WT enzyme was purified
from the same P. pastoris expression system [7].
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Figure 2-4: Western Blot of purified WT and mutant αGal.
Purified WT and mutant enzymes were subjected to Western blotting using a polyclonal
antibody raised against residues 55–64 and 396–407 of αGal. (a) Blot at shorter and (b)
longer exposure.
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Mass spectrometry of a purified mutant enzyme
Two possible amino terminal amino acids, glutamate or leucine, could be produced in P. pastoris
depending upon the selection of the signal peptidase, Kex2 or Ste13 (Figure 2-1). Due to the fact
that potential improper amino terminal processing may have an effect on kinetics, we selected
one of the purified mutant enzymes (Δ6) for mass spectrometry analysis in order to identify the
amino terminal sequence of this enzyme. This analysis also made it possible to provide
independent verification of the expected changes in the C-terminal amino acid sequence
predicted by in vitro mutagenesis (Figure 2-1, 2-2).
The mature form of the enzyme (signal peptide removed; [119]) produced in humans begins with
a leucine codon (Figure 2-1, 2-2). Therefore, tandem mass spectrometry following tryptic
digestion of the Δ6 αGal purified from P. pastoris could produce tryptic peptides EALDNGLAR
or LDNGLAR, depending upon the use of the Kex2 or Ste13 protease sites (Figure 2-1, 2-2). A
putative LDNGLAR peak was identified in the MS spectra with an m/z of 379.71, consistent
with the (M+2H)2+ state of this peptide, while no peaks consistent with an EALDNGLAR
peptide were found. We cannot eliminate what we consider to be the less likely possibility that
the failure to detect the EALDNGLAR peptide may be due to the failure of the peptide to ionize
in this MS experiment. Further fragmentation of the m/z = 379.71 associated peptide peak
produced an MS/MS spectrum containing 4 of 7 possible y-ions and 4 of 7 possible b-ions from
the expected fragmentation pattern of a hypothetical LDNGLAR peptide (Figure 1-5a). This
result indicates that the Ste13 signal peptidase of P. pastoris generates an enzyme with an amino
terminus identical to the enzyme produced in humans.
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Figure 2-5: Mass spectrometry of purified Δ6 αGal
MS/MS spectra obtained from parental MS ions (a) m/z = 379.71 and (b) m/z = 1064.03 corresponding
to a C-terminal and N-terminal peptide, respectively. Product ion peaks are annotated according to their
predicted [M+H]+ forms. Annotations in red and blue correspond to b-series and y-series ion fragments,
respectively.

A search for a Δ6 C-terminal tryptic peptide of SHINPTGTVLLQLENTMQM (Figure 1-2)
yielded a matching MS m/z = 1064.03 peak consistent with its (M+2H)2+ state. Further
fragmentation also produced an MS/MS spectrum containing 4 of 19 possible y-ions and 9 of 19
possible b-ions consistent with the anticipated sequence (Figure 1-5b). This result confirms the
predicted C-terminal deletion of 6 amino acids and confirms the efficacy of the mutagenesis
protocol used to produce this mutant enzyme.
Thus, the purified Δ6 αGal mutant possesses an N-terminal sequence corresponding to the
mature form of αGal and a C-terminal sequence truncated by six amino acids.
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Thermostability and pH optima of WT and deletion mutants of αGal

Figure 2-6: Thermostability profiles of WT and mutant αGal.
Stability of recombinant WT and Δ2 to Δ10 mutant αGal at 30°C (a), 40°C (b),
and 50°C (c) at pH 5.5 as monitored by fluorescent enzyme assay. Initial
activities ranged from approximately 300 to 1,900 units/mL for all enzymes
assayed. % Activity is normalized against activity at t = 0 mins. Data points for
(a) and (c) are the mean of a triplicate measurement with error bars equivalent to
± 1 standard deviation. Data points for (b) are the results of a single
measurement. MUG was used as the substrate for enzyme assay.
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Preparations of purified WT and mutant αGal show similar thermostability profiles at 30°C,
40°C, and 50°C, with activity half-lives of 30, 25 and 17 minutes, respectively (Figure 2-6). The
general trend of these profiles agrees with previous results [120]. All enzymes show optimal
activity near pH 4.5 (Figure 2-7) in accord with previous reports for WT αGal [16, 114, 121,
122], and there is no significant difference in the activity optima of purified WT and mutant
αGal.

Figure 2-7: pH activity curves of WT and mutant αGal.
pH activity curves for WT and Δ2 to Δ10 mutant αGal. % Activity is normalized
against each enzyme’s peak activity. Data points are the mean of a triplicate
measurement and error bars are ± 1 standard deviation. MUG was used as the
substrate for enzyme assay.
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Kinetic analysis of WT and C-terminal deletion mutants
The values for Km and Vmax for WT enzyme (Table 2-3a) are in accord with published values
(Table 2-5). The range of Km and Vmax values for the enzymes purified from several sources in
various laboratories over a period of more than 30 years (Table 2-5) are in good agreement and
the observed subtle variations are in the range expected. However, more precision is expected for
measurements recorded for enzymes purified from the same source in a single laboratory at one
given time (Table 2-3a). Substrate saturation curves (Figure 2-8a) and the calculated values for
Km, Vmax, kcat, and kcat/Km using the MUG substrate (Table 2-3a) reveal differences in the
enzyme activity of the mutants compared to WT. Deletions of 2, 4, 6 and 10 amino acids
approximately double the kcat/Km (0.8 to 1.7-fold effect; 29/34.4 = 0.8 and 58.3/34.4 = 1.7)
while a deletion of 8 amino acids decreases the kcat/Km (7.2-fold effect; 34.4/4.78 = 7.2). There
are corresponding changes in the Vmax values and deletions of 2, 4, 6 and 10 amino acids
approximately double the Vmax (1.5 to 2.2-fold effect; 4.89/3.36 = 1.5 and 7.29/3.36 = 2.2)
while a deletion of 8 amino acids decreases the Vmax (4.5-fold effect; 3.36/0.742 = 4.5). There
are also smaller differences in the Km values of the C-terminal deletion mutants compared to the
WT (Table 2-3a). The Vmax data presented for the Δ8 (0.742 ± 0.21) and WT (3.36 ± 0.29) are
derived from multiple assays from three and two independent enzyme samples, respectively, and
this indicates the reliability of this data and adds strength to the interpretations of the data from
the single enzyme preparations used for the other deletion mutants.
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Table 2-5: Literature Values for Km and Vmax for the WT Human αGal.
Km (mM)

Vmax (mmole/hr/mg)

Source

Reference

year

1.6

NA

Placenta

[13]

1978

2.9

1.7

Liver

[16, 17]

1979

1.9

NA

Plasma

[25]

1979

2.5

NA

Spleen

[25]

1979

2.0

2.8

Spleen

[26]

1981

2.3

2.3

Sf9 insect cells

[27]

2000

2.0

4.8

Replagal

[3]

2003

2.0

4.8

Fabrazyme

[3]

2003

4.0

3.3

Fabrazyme

[28]

2009

2.8

2.6

COS-7 cells

[29]

2007

4.5

3.3

COS-7 cells

[30]

2011
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Figure 2-8: Substrate saturation curves of WT and mutant αGal.
Purified WT, Δ2, Δ4, Δ6, Δ8and Δ10 αGal were enzyme assayed in 0.3 to 2.0 mM
MUG (Figure 2-8a) and in 7 mM to 50 mM PNPαGal (Figure 2-8b) to measure initial
velocities (mmol product per hr/mg enzyme). Km and Vmax parameters were extracted
and compiled in Table 2-3. The figure indicates fits of Michaelis-Menten hyperbolas to
experimental data indicated as mean ± one standard deviation.

The effects of the C-terminal deletions on the kinetic properties of the enzyme using the artificial
substrate MUG (Table 2-3a) could be due to alterations in the inherent catalytic mechanism of
the enzyme [21]. Alternatively, the altered kinetic properties could be due to changes in the
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affinity of the enzyme for specific structural components of the artificial substrate, MUG. In this
context, it is of interest to measure these kinetic parameters with an alternative substrate such as
PNPαGal. The results (Table 2-3b, Figure 2-8b) indicate that there are similar changes in kinetic
parameters using PNPαGal as the substrate, including increases (2.2-fold effect; 9.18/4.18 = 2.2)
and decreases (3.2-fold effect; 4.18/1.31 = 3.2) in the kcat/Km for the specific C-terminal
deletion mutants (Δ10 and Δ8, respectively). Taken together, these results suggest that the Cterminal deletions likely affect some aspect of the inherent catalytic mechanism of the enzyme.

Discussion
This is the first report to establish in a quantitative manner that the C-terminal residues of αGal
act as a modulator of catalytic activity. Our results confirm the general results of Miyamura et al.
[2] that C-terminal deletions of 2, 4, 6 and 10 amino acids increase the kcat/Km compared to
WT. However, our results differ in that we find that a deletion of 8 amino acids results in a
decrease of kcat/Km. It should be noted that there are numerous experimental differences
between these two reports. For example, our analysis used purified enzymes expressed in P.
pastoris and their experiments measured αGal enzyme activity during transient infection of
COS-1 cells. There could be differences in αGal mRNA or protein stability between P. pastoris
and COS-1 cells, and other proteins in the cytoplasm of P. pastoris or COS-1 cells could interact
directly or indirectly with the αGal protein to affect its catalytic activity.
It is of interest that the two recombinant protein therapeutics, Fabrazyme (agalsidase-beta) and
Replagal (agalsidase-alfa) contain C-terminal heterogeneity with truncated species lacking either
one or two C-terminal residues [3]. Fabrazyme contains 69.7% full length protein with 7.6% Δ1
and 22.8% Δ2, while Replagal contains only 5.7% full length, with 73.2% Δ1 and 21.1% Δ2.
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These authors attribute the C-terminal heterogeneity to in vivo proteolytic processing of an
undefined nature. These commercial enzymes do not differ significantly from the WT in Km and
Vmax (Table 2-5) in spite of this degree of protein heterogeneity [3]. The significantly increased
Vmax of some of the mutants with C-terminal deletions suggests the basis for an improved
treatment for Fabry disease.
These results also illustrate the principle that in vitro mutagenesis can be used to generate αGal
derivatives with improved enzyme activity. The potential for improved catalytic activity for this
enzyme is illustrated by the existence of closely related enzymes with 3-fold to 250-fold higher
activity (Table 2-6). A direct comparison of relevant amino acid residues between the human and
related enzymes suggests the basis for rational in vitro mutagenesis to improve catalytic activity
of the WT human enzyme. In this context, it is likely that mutants which show altered catalysis
against the MUG substrate used here also have a correspondingly higher rate of catalysis against
the natural substrate, but this possibility needs to be tested directly.
Clinical trials for ERT show seroconversion frequencies of more than 50% for males treated with
0.2 mg/kg agalsidase-alfa [51] and 88% for 1.0 mg/kg agalsidase-beta [50, 123]. Increasing the
dose of administered enzyme in seroconverted patients raised antibody titers in some patients
[123, 124]. IgG antibody status shows a strong association with serious infusion associated
adverse reactions [124]. IgG positive serum from Fabry patients exhibits in vitro neutralization
of enzyme activity [125]and lessens targeting to key disease organs in a Fabry mouse model
[126]. The disease marker of urinary globotriaosylceramide levels is increased in seropositive
patients as compared to seronegative patients [123, 125]. It has been proposed that higher doses
of administered enzyme could overcome the inhibitory effect of antibodies on treatment
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effectiveness [123]. By using an enzyme that is more active on a per mg basis, a therapeutic
effect equivalent to WT is achievable through administration of a lower dose. The ability to
administer a lower dose of the enzyme will intern decrease the amount of harmful antibodies
produced in patients making this a better alternative to the current therapy. Future studies should
include examination of these mutant enzymes relative to WT in cultured cells [15] and in mouse
models [127, 128].
The specificity constant (kcat/Km) has a maximum possible value determined by the frequency
at which enzyme and substrate molecules collide in solution [129] If every collision results in
formation of an enzyme-substrate complex, diffusion theory predicts that kcat/Km will attain a
value of 108 – 109M−1s−1 [129]. The kcat/Km of WT human αGal is approximately 5.49 ×
103M−1s−1 (Table 2-6) suggesting the possibility that altered forms of the human enzyme may
exist that have higher catalytic activity. A BLAST analysis [10] identified the 33 sequences most
closely related to αGal and kinetic parameters have been reported for 6 of these enzymes (Table
2-6). These enzymes share a high degree of sequence and structural similarities and are all in the
same family 27 of glycosyl hydrolases [10]. There is a broad range in the values reported (Table
1.6) for Km, kcat and kcat/Km. Thus, a detailed structural comparison of these enzymes may
permit the identification of key amino acid residues that influence these kinetic parameters.
Truncation of the C-terminus of the coffee bean α-galactosidase (Figure 2-9) showed that
deletion of one or two amino acids decreases activity and deleting 3 or more residues abolished
activity completely [130]The results with the coffee bean enzyme contrast those presented here
for the human enzyme. Both results however demonstrate that the C-terminus of αGal is critical
for enzyme function.
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We examined a superposition between the crystal structure of the human enzyme and a
homology model of the coffee bean enzyme (see Methods) to explore a structural basis for this
biochemical dissimilarity. The N-terminal catalytic (α/β)8 domain superimposes very well
(RMSD of 0.729 Å over 1126 total atoms) while the C-terminal antiparallel β-domain
superimposes poorly (RMSD of 2.494 Å over 342 total atoms). A primary sequence alignment

Figure 2-9 : The C-termini of human and coffee αgalactosidase.
The crystal structure of human αGal and a predicted model of the coffee homolog were
superimposed. Underlined terminal residues, (MSLKDLL) in humans and (Q) in the coffee
bean enzyme, indicate amino acids that could not be modeled due to conformational disorder.
The terminal amino acid of the coffee enzyme (glutamine, Q) aligns with (threonine, T) in the
human enzyme and is located 9 amino acids (MQMSLKDLL) from the C-terminus of the
human enzyme.

shows a comparable trend; the catalytic domain shows high sequence conservation while the Cterminal domain does not. An alignment of the C-terminal ends of the human and coffee bean
enzymes is presented (Figure 2-9) indicating secondary structure alignment (left) and primary
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sequence alignment (right). If the C-terminal domain governs a conserved mechanism of
enzymatic regulation across the human and coffee homologs, then the deleterious effect of
removing C-terminal amino acids from the coffee enzyme is consistent with observations made
by Miyamura et al. [2] on the human enzyme.
Because of the low sequence homology observed in the C-terminal residues it can be
hypothesized that the effect on the catalytic activity due to C-terminus deletions in both the
human and coffee bean α-galactosidase is due to disruption of the enzyme’s three-dimensional
structure. This disruption could have an effect on enzyme dimerization, the ability to bind
substrate, or potential interactions with other molecules in the cell.
The most straightforward expectation of a series of C-terminal deletions is a direct correlation
between the extent of the deletion and the effect on enzyme activity. In this sense, the reduced
activity of the Δ8 mutant relative to the other C-terminal deletion mutants (Table 2-3) is
unanticipated. However, we note that similar effects have been reported by others who carried
out C-terminal deletion studies, including the IN269 mutation for the integrase of HIV [131], the
Δ8 and Δ9 mutants of the thymidine kinase of Epstein-Barr virus [132], and the D5 and D10
mutants of the plant vacullar H (+)-pyrophosphatase [133] Differential proteolysis may also
explain why the Δ8 construct does not follow the same trend as the other mutants.
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Figure 2-10: C-terminal Distance from Secondary Binding Site and Opposite Active Site.
The homodimeric crystal structure of αGal (PDB ID 1R47) solved by [10] is displayed in two
different perspectives. Distance relationships relative to one out of the two possible C-termini are
discussed. The carbon backbone is rendered in a ribbon format. The C-terminus on monomer A is
separated by 20 Å to 25 Å from a secondary binding site for β-D-galactopyranose on the same
monomer [21] which is marked by Tyr 329 rendered as spheres. The C-terminus on monomer A is
also separated by 45 Å to 50 Å from the active site of monomer B which is marked by the α-Dgalactopyranoside ligand also rendered as spheres.
The crystal structure of αGal [10]revealed that the last visible residue of the C-terminus is
separated by approximately 45 Å from the active site on the opposite monomer and is too far to
have a direct effect on catalysis. However, within the same crystal structure (PDB 1R47) we
measured C-terminal end to be only 20–25 Å away from a second ligand-binding site for βDgalactopyranose [21], demarcated by Tyr329 (Figure 2-10). Directly visualizing a putative
interaction between the C-terminus and the second binding site is not possible because Cterminal disorder limits resolution to the 7th or 8th amino acid from the full-length C-terminal
end. If these 7 or 8 amino acids were to adopt a fully-extended conformation, they would span a
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distance of 22–26 Å (see Methods), bringing the C-terminus within potential contact distance of
the secondary binding site. A crucial missing detail is the functional significance of the
secondary site. It may serve as a site for small molecule chaperoning [21]. It also might
participate allosterically in a manner similar to phosphofructokinase-1, that is allosterically
activated by ADP [134, 135], a product of the enzyme’s ATPase function. The ligand that binds
the secondary site on αGal is β-D-galactopyranose [21], which is the mutarotated product of the
enzyme’s glycoside hydrolase function. A dynamic interplay may exist between the C-terminus,
the secondary site and its ligand to affect the catalytic activity of αGal through allostery or
structural stability of the protein. Further mechanistic studies will be needed to work out the
exact relationships between these putative components and their relevance to in vitro catalysis.
Due to the lack of direct contact between the carboxyl-terminal amino acids and the catalytic site
of αGal, the explanation for the effect of the deletions of the carboxyl-terminal amino acids is not
obvious. Another hypothesis to be tested is that αGal is in a class of enzymes like the E. coli
dihydrofolate reductase [136-140], in which tunneling and coupled motion accounts for the
effects of mutations distal from the catalytic site on enzyme function.

Conclusions
C-terminal truncation mutants of αGal were constructed, expressed and purified from P. pastoris
using Con A and Thio-Gal affinity column chromatography. Michaelis-Menten parameters were
measured on the purified mutants. Deletion of 2, 4, 6 and 10 amino acids approximately doubles
kcat/Km relative to WT (0.8-1.7-fold effect) while deleting 8 amino acids decreases kcat/Km
(7.2-fold effect). Mutants with increased activity are proposed as an improved alternative therapy
over WT enzyme for Fabry disease patients. These results also illustrate the principle that in vitro
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mutagenesis can be used to generate αGal derivatives with improved enzyme activit
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Chapter 3 : Uptake of α-Galactosidase A by the Scavenger
and Mannose Pathways
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Abstract
ERT for Fabry disease has so far proved only partially successful in preventing adverse
outcomes, presumably due to the lack of efficient delivery of therapeutic αGal to many affected
tissues. ERT improves patient symptoms but fatal outcomes persist and storage of the toxic
enzyme substrate, GB3, remains in many of the affected organs. Our approach is the
development of derivatives of the enzyme with improved uptake properties targeting disease
affected tissues such as the brain and in particularly endothelial cells, a major site of
accumulation of GB3. A relatively unexplored possibility is to target therapeutic enzyme to the
ubiquitous SR uptake system. SRs are abundant on endothelial cells that are not effectively
targeted by current ERT mediated by the M6P uptake system used for treatment of LSDs such as
Fabry disease. In addition, these treatments do not pass the blood-brain barrier (BBB). The
scavenger receptors SR-A3, SR-A5, and SR-BI are expressed in brain capillary endothelial cells
and promote receptor-mediated endocytosis and transcytosis for delivery of drugs across the
BBB. Production of αGal in Pichia results in mannose terminated recombinant enzyme. This
enzyme is hypothesized to target the MR that is known to be expressed in many cell types
including endothelial, smooth muscle, and kidney mesangial cells.
We introduced negative charges on HSA and the recombinant human αGal by treatment with cisaconitic anhydride to generate terminal carboxyl groups (Aco-αGal). We tested the uptake of
αGal using Fabry fibroblasts and endothelial cells. Targeting to the SR was tested by monitoring
uptake in cells overexpressing the murine scavenger receptor A (U2OS-SRA). Enzyme uptake
in cells in culture was monitored by direct enzyme assay and by confocal microscopy using
Alexa-tagged-αGal (Alexa-αGal) using fixed cells and a live-cell assay for continuous uptake
analysis. Our preliminary results indicate targeting of αGal produced in Pichia to both the SR
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and MR uptake pathways with enhanced uptake of aconitylated αGal after short incubation times
(30 min) in Fabry endothelial cells. The ability to target αGal to the MR and SR pathways would
permit enhanced effectiveness of the currently available M6P-dependent ERT. These results may
lead to improved approaches for ERT for Fabry disease patients and for other LSD patients
including targeting accumulated substrate in endothelial and neurological tissues dependent upon
transit of the BBB.

Introduction
The relative tissue and cellular distribution of agalsidase alfa (Replagal™, therapeutic produced
in a cultured human cells), was shown to be heterogeneous following a single intravenous
injection in a mouse knockout model of Fabry disease [141]. Therefore, in addition to antibody
formation, enzyme access to certain sites of tissue substrate storage may be another limiting
factor of ERT. Currently approved ERT for Fabry disease [97, 142] was assumed to depend upon
the M6P receptor for uptake of αGal. However, the M6P receptor is present on some but not all
cell types that are affected in Fabry disease. Endothelial cells, a major site of GB3 accumulation
(Figure 3-1), lack M6P receptors [15, 143]. Despite recent studies suggesting uptake of
phosphorylated enzyme by the M6P receptor at the BBB in newborn mice [144], or in adult mice
using epinephrine as an inducer [145] or in the presense of much higher doses that used in ERT
[146] in the LSD Mucopolysaccharidosis type IIIA (MPS IIIA). This uptake however was shown
to be very low[147], in addition maintaining high plasma levels of the lysosomal enzyme used in
ERT to achieve this uptake would most likely result in a severe immune response. As is the M6P
pathway is known to not operate substantially at the BBB [58, 148, 149]. It was suggested that
M6P mediated uptake of αGal is not representative of the mechanism of uptake of the enzyme in
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cells that are a focus of storage and injury in Fabry disease [15]. Recombinant human αGal
produced in plants removes accumulated GB3 even though these enzymes lack terminal M6P
residues [1, 70], indicating that M6P receptors are not essential for enzyme uptake. Patients with
I-cell disease lack M6P groups on lysosomal enzymes but still transport some enzymes to the
lysosome, including αGal, using other uptake pathway(s) [150, 151].
SRs were first defined in 1979 by Brown and Goldstein as macrophage receptors that mediate
endocytosis of modified low density lipoprotein (LDL) such as acetylated LDL (Ac-LDL) and
oxidized LDL leading to foam cell formation and were shown to play a role in the pathogenesis
of atherosclerosis. Currently this definition has been broadened such that SRs are now
categorized as a family of molecules sharing the ability to bind polyanionic ligands. Structurally
diverse, including both membrane bound and soluble proteins, they are involved in the
recognition and/or endocytosis of negatively charged molecules [152]. SRs are grouped into
eight different classes (Class A-H) based on shared structural domains (Figure 3-1)[153]. Despite
these structural differences, mutagenesis studies have shown that the ligand-binding domain of
many of these receptors contains arginine or lysine clusters mediating electrostatic interactions
with the negatively charged ligands [154]. Ligand-binding can activate signaling cascades
leading to diverse cellular functions or the SR/ligand complexes can undergo endocytosis leading
to degradation or accumulation of the ligand in the endosome-lysosome system[154].
The ligands for the SRs involve negatively charged proteins, such as aconitylated, maleylated
and succinylated albumins, modified low-density lipoproteins, and polynucleotides [155].
Negatively charged albumins can participate as drug carriers for delivery to SRs [156].
Successful receptor-mediated delivery to macrophages in vitro used low-molecular-weight
antitumor agents conjugated with maleylated albumin [157-159]. Maleylated albumin was used
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as a targeting carrier for a photosensitizer [160] and a macrophage activating peptide [161, 162]
using SRs. In addition, direct succinylation targeted delivery of catalase to liver nonparenchymal
cells [156].
The delivery of an enzyme by way of the SR for the therapy of LSDs builds on previous
techniques for specific delivery of molecules to cells. For example, sterically stabilized
liposomes derivatized with polyethylene glycol were used to deliver doxorubicin to squamous
cell lung carcinoma cells by means of specific antibodies attached to the liposome surface [163].
In addition, others have demonstrated massive targeting of liposomes that are surface modified
with anionized albumins, one of the techniques we propose here as a future study, to hepatic
endothelial cells [164]. This group also demonstrated the successful targeting to the SR of
formaldehyde treated HSA [165] and oxidized human LDL [166]. In addition, efficient hepatic
uptake of negatively charged proteins and uptake of soluble antigens by dendritic cells through
targeting to the SR has been shown [4, 167].
The SR family of uptake systems are highly active on several tissue types including
macrophages, monocytes, platelets, endothelial, smooth muscle, and epithelial cells (Figure 31)[154]. An important site of accumulation of αGal substrates, including GB3 and other related
compounds, is in endothelial cells. In a study of the effect of these SRs, the delivery of acetylated
HSA to endothelial cells was described as “massive”, with complete clearance from the blood in
30 minutes, while in the control 80% was still in the blood [164].
SR-AI and SR-BI are expressed at brain capillary endothelial cells and they have been shown to
have a very important role at the BBB [17, 24]. The current ERT is prevented from accessing the
central nervous system because of the BBB. The SR-BI receptor has been shown to play a role
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in the transport of cholesteryl esters at the BBB. This makes these receptors suitable for targeting
ERT in Fabry disease to the brain [168].
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Figure 3-1: Domain architecture of the different classes of scavenger receptors [22]. Their ligands, and
expression profiles [23, 24].
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Aconitylation was hypothesized to be a good means
of adding negative charge and targeting to the SR for
several reasons. Firstly, with aconitylation a net
negative charge of three is added for each surface
lysine, which is modified; maximizing the potential
of adding negative charge to our enzyme (Figure 32). Secondly, aconitylation is shown to be reversible
at acidic pH (Figure 3-3) and this will generate a
normal and fully active αGal at the low pH of the

Figure 3-2: Reaction of surface Lys
with cis-aconitic anhydride.
Cis-aconitic anhydride coupling to Lys
residues introduces a net three negative
charges for each Lys residue.

lysosome after ERT in Fabry disease patients.
Chloroquine, an inhibitor of lysosomal acidification, blocked deacylation of aconitylated
ovalbumin after lysosomal uptake in vivo [4]. Lastly, saturating SRs with aconitylated human
serum albumin (Aco-HSA), in vivo, produces no immune response (Figure 3-4)[6].

Figure 3-3: Aconitylation is reversible at the acidic pH of the
lysosome [4].
Treatment of succinylated (Suc-Ova), maleylated (Mal-Ova), and
aconitylated (Aco-Ova) ovalbumin (OVA) at 37° in phosphate
buffered saline at pH 5.0 (a) or 7.4 (b)[4]. Reversal of aconitylation
will generate a normal and fully active αGal at the low pH of the
lysosome after ERT.
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A SR system present in the mononuclear phagocytic system on endothelial and Kupffer cells
(Figure 3-4) is responsible for the uptake and clearance of Aco-HSA [6]. High plasma
concentrations (up to 1 mg/ml) of 125I-Aco-HSA did not affect blood coagulation or lymphocyte
proliferation, and showed no acute or sub-acute toxicity [6]. The lack of an immune response to
Aco-HSA (Figure 3-4) was indicated by sensitive lymphocyte proliferation assays showing that
lymphocyte functions were not significantly altered following immunization of rats with
complete Freund's adjuvant (an immunopotentiator) for a four-week period [6]. Liver and spleen
uptake of 125I-Aco-HSA was selectively blocked by the specific SR inhibitors polyinosinic acid
(PolyI) or formaldehyde-treated human serum albumin [6]. These results demonstrate the
presence of high levels of Aco-HSA distributed throughout the body.

Figure 3-4: Saturation of scavenger receptors in liver, spleen, kidney, and blood
endothelium [6].
Tissue distribution of 125I-Aco-human serum albumin 10 min after intravenous injection
to male rats in the absence (control) and presence of the scavenger receptor inhibitors
Poly-I or formaldehyde-treated human serum albumin (Form-HSA) [6]. There was no
detectable immune response to Aco-HSA following immunization of rats for four
weeks using complete Freund's adjuvant. 55
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Aco-αGal can potentially target diverse sites of accumulation of GB3 substrate in Fabry disease
patients (Figure 3-1), including kidneys, lungs, cardiomyocytes [169, 170], virtually all
microvascular endothelial cells, and potentially the brain. Development of an efficient and
widespread delivery system for αGal can minimize ERT dose and frequency and this could
reduce the immune response to αGal [34, 37, 50, 51, 53-55, 81, 99, 171-173].
Because of the amount of genetic, clinical, and structural information available for Fabry disease,
it can serve as model for the entire family of LSDs [14]. Therefore, if successful, these
approaches could be applied to enzyme therapy for other LSDs. While ERT can be expected to
extend life spans, most patients suffer from ill-defined infusion-associated reactions. Therefore,
any improvement in treatment that leads to more effective therapeutic effects or less frequent
infusions would markedly improve the lives of Fabry disease patients and other patients
receiving ERT for LSDs.

Methods and Research Design
Purification of recombinant αGal
High-cell-density fermentation was carried out as previously described using a 7L bioreactor
[20]. Bioreactor supernatant was passed through a 0.2 µm hollow fiber filter (Spectrum Labs,
No. M22M-300-01N) and subjected to diafiltration using a 50 kDa pore size hollow fiber filter
(Spectrum Labs, No. M25S-300-01N) against Buffer A (10 mM NaHPO4, pH 6.5, 0.02% NaN3,
and 0.05 mM PMSF). The resulting supernatant was applied to a DEAE Sepharose Fast Flow
(GE Healthcare, No.17-0709-01) column, pre-equilibrated with 5 column volumes Buffer A.
Elution of αGal was carried out using a 0 to 1M NaCl gradient in Buffer A. Elution was
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discontinued when the absorbance at 280 nm and enzyme assays showed negligible presence of
protein and αGal activity. The DEAE elution tubes with sufficient αGal activity were pooled and
subjected to diafiltration using the previously described 50 kDa pore size hollow fiber filter
(Spectrum Labs, No. M25S-30001N) against binding buffer (25 mM citrate-phosphate buffer,
pH 4.8 containing 0.1 M NaCl). The diafiltrated product was applied to an immobilized-Dgalactose gel column (Thio-Gal, Pierce No. 20372) pre-equilibrated with binding buffer. The
column was washed with 5 column volumes of binding buffer and αGal was eluted with elution
buffer II (25 mM citrate-phosphate buffer, pH 5.5, 0.1 M NaCl, 0.1 M D-galactose) over 1.5
column volume blocks separated by 12-hour soaks. Fractions were assayed for enzyme activity
and protein concentration and pooled, this pool was chosen as the sample to be used in uptake
studies. This two-column purification is simpler and faster than our previous purification
methods that used two [20] three [9] or four [7, 8] columns and the yield, degree of purity, and
final specific activities were similar for all three methods.

Enzyme assay
Activity of αGal was assayed using the synthetic substrate MUG as described [7] with
modifications to a microtiter plate format (below). Enzyme activity is measured in units/ml
where one unit is defined as the amount of enzyme required to convert 1 nmole of MUG to 4methylumbelliferone in one hour at 37°C. An aliquot of 3 µl was added to 27 µl of enzyme assay
buffer (5 mM MUG in 40 mM sodium acetate buffer, pH 4.5). This mixture was incubated at
37°C and 10 µl aliquots were taken at two time points and added to 290 µl of 0.1 M diethylamine
in a microtiter plate to stop the reaction. The fluorescence of each sample was measured at an
excitation wavelength of 365 nm and an emission wavelength of 450 nm using a Tecan Infinite
F200 microtiter plate reader. A standard curve of 10 µl of 0 – 50 nM 4-methylumbelliferone
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dissolved in MeOH in 290 µl of 0.1 M diethylamine was used to quantitate MUG cleavage at
specific time intervals. Analysis of the effects of MeOH indicated no effect on the 4methylumbelliferone standard curve.

Protein assay
Absorbance at 280nm on A NanoDropTM 2000/2000c was used to quantify purified recombinant
protein. An Extinction coefficient of 117,475 M-1 cm-1 was calculated for αGal [174] and used
for A280 measurements with a molecular weight of the monomer, 45 kDa. A standard Bradford
protein assay was also used to confirm results. In short, 10 µl of the. A standard Bradford
protein assay was also used to confirm results. In short, 10 µl of the sample/standard was
combined with filtered 4X diluted Coomassie dye and incubated for 5 minutes. The absorbance
was measured at 595 nm using a Tecan Infinite F200 microtiter plate reader. A standard curve of
0 - 400 µg/ml BSA was used.

Electrophoresis analysis
Samples were mixed with an equal volume of reducing sample buffer (Bio-Rad Laemmli sample
buffer with 5% β-mercaptoethanol) and heated for 5 minutes at 95°C before loading on a MiniProtean TGX Precast Gel 4–20% (w/v) (Bio-Rad No. 456-1094). Bands were visualized by
Coomassie blue staining via the modified Fairbanks protocol [112].

Cell culture
FFB (GM2775, Coriell Institute for Medical Research, Camden, NJ) and healthy non-fetal tissue
fibroblasts (NFB) (GM04390, Coriell Institute for Medical Research, Camden, NJ) used as a
control were grown to confluency in MEM, GlutaMAX™ (Gibco) supplemented with 10% FBS,
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Antibiotic-Antimycotic, and MEM nonessential amino acid solution (ThermoFisher) in T-75
flasks at 37 °C and 5% CO2.
Human Dermal Microvascular Endothelial Cells (HMVEC, Lonza, Walkersville, MD) and the
immortalized Fabry endothelial cell line-1 (IMFE-1) cells [175] were generously donated by
Prof. R. Schiffmann (Baylor Research Institute), and were plated into T-75 flasks and grown to
confluency in the EGM-2MV kit (Lonza, Walkersville, MD) at 37 °C and 5% CO2 as per that
labs recommendation before the experiment.
Human osteosarcoma U2OS (HTB-96TM) cells from ATCC were grown in McCoy’s 5A
medium with 1% Pen-Strep and10% FBS in tissue culture treated T-75 flasks. U2OS-SRA cells
(human U2OS osteosarcoma cells over-expressing the murine scavenger receptor A) were
generously donated by Professor F. Maxfield (Weill Cornell Medical College) and grown in
McCoy’s 5A medium with 1% Pen-Strep, 1 mg/ml G418 and 10% FBS on non-tissue culture
treated petri plates at 37 °C and 5% CO2.

Evaluation of uptake using enzyme assay
Fibroblast and endothelial cells were grown till 80-90% confluence on 6-well plates. The
medium was removed and 2ml of culture medium containing BSA (5 mg/ml) and appropriate
concentration of the purified recombinant αGal was added. plates were then incubated at 37˚C
and 5% CO2 for indicated times. Following this incubation, the medium was removed, followed
by three washes with PBS. Cells were then harvested using trypsin/EDTA and precipitated by
centrifugation. Each cell pellet was re-suspended in 50 µl of 1X Buffer A. Cells were then
ruptured by freeze-thawing three times and protein and enzyme assays done on the cell extracts.
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[7, 9, 166], [15] Uptake of human αGal was measured by enzyme assay using the synthetic
substrate MUG.

Evaluation of uptake using confocal microscopy
Recombinant αGal was labeled with Alexa Fluor 488 according to the instructions of the
manufacturer (Molecular Probes). Alexa tagging was done in Modified Buffer A at a pH of 7.5.
Degree of Labeling (DOL = moles dye / moles protein) of the sample was determined based on
obtaining the protein concentration by absorbance at 280 nm and at 494 nm in a NanoDropTM
2000/2000c.
FFB, IMFE1 and U2OS-SRA cells were grown to near confluence on an 8-well Nunc™ LabTek™ II Chambered Coverglass (Thermo Fisher Scientific, Catalog# 155409) incubated at 37°C
and 5% CO2 with Alexa Fluor 488-labeled αGal (5 µg/ml) for variable time lengths with or
without inhibitors in the presence of 5 mg/ml BSA to increase enzyme stability. Cells were
washed with PBS and fixed with 4% paraformaldehyde for 10 min at room temperature. Cells
were then washed with PBS 3 times and covered with the ProLong® Diamond Antifade
Mountant with the nuclear stain DAPI (4',6-diamidino-2-phenylindole) before imaging in a Zeiss
Confocal LSM 710. Cells were counterstained with LysoTracker Red DND-99 (L-7528;
Molecular Probes) for 2 hours before fixation for co-localization analysis. Uptake was quantified
using ImageJ.

Live cell imaging
Live cell imaging was performed using a ZEISS LSM 880 Super-Resolution confocal laserscanning microscope with Airyscan and CO2 incubator was used. Cells were incubated with
Alexa488 tagged enzyme in FluoroBrite™ DMEM and Prolong Live Antifade Reagent
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(Invitrogen) in the presence of 5 mg/ml BSA to increase enzyme stability. Images were acquired
every 10 minutes. ImageJ was also used to quantify live cell images. Cells were incubated with
LysoTracker Deep Red to visualize lysosomes and evaluate uptake of enzyme to lysosomes (colocalization).

Quantification of uptake in confocal images
ImageJ was used to quantify the fluorescence intensity of enzyme and lysosomes and to
determine colocalization. Images were loaded on the ImageJ software and the channels
separated. Particle analysis was performed on both the green and red channel images (Figure
3.6). Co-localization of the LysoTracker Red and αGal particle images was visualized using the
co-localization highlighter plugin. (Figure 3-9) Particle analysis was performed on the colocalized image generated as well as the Alexa and LysoTracker channels (Figure 3-10).

Aconitylation
Aconitylation was carried out as per published methods with minor changes to accommodate
αGal instability at high pH (Figure 3-19) [165, 167, 176]. The surface lysine residues of samples
in buffer at a pH of 7.5 were reacted with excess cis-aconitic anhydride and stirred at 4°C for
1hr. The degree of modification of lysine residues was assessed by estimating the loss of free
amino groups as measured by trinitrobenzenesulphonic acid assay (TNBS) [18] or
fluorescamine [177] assay post removal of excess anhydride and using a glycine standard curve.
In addition, the pre-and post aconitylated samples were analyzed using native PAGE and 2D
protein electrophoresis, where the first dimension is an isoelectric focusing gel (IEF) and the
second dimension is an SDS-PAGE. IEF gels can be used to detect minor changes in the protein
charge.
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Quantification of modification by TNBS and fluorescamine assay
The TNBS component reacts readily with primary amino groups of amino acids in aqueous
format at basic pH to form yellow adducts which can be monitored at 345 nm. Assay samples
were dialyzed in 0.1 M sodium bicarbonate buffer (pH 8.5). The supplied 5% TNBS solution
(Thermo Fisher Scientific Inc.) was diluted 500-fold in 0.1 M sodium bicarbonate buffer (pH
8.5). 0.5 mL of the diluted TNBS solution was added to 1mL of protein solution (approximately
1 mg), mixed and incubate at 37 °C for 2 hours. 0.5 mL of 10 % SDS and 0.25 mL of 1 N HCl
was added to each sample/standard to stop and stabilize the reaction. Absorbance of the solution
was measured using a Tecan infinite F200 at 335nm.
Fluorescamine also reacts with primary amino groups of amino acids [177]. 150 µl of 0.05 M
sodium phosphate buffer pH 8.5 and 50 µl of 1.08 mM fluorescamine dissolved in acetone were
added to an aliquot of 50 µl of the sample and standards, mixed and incubated at room
temperature for 12 minutes. The fluorescence of each sample was measured at an excitation
wavelength of 400 nm and an emission wavelength of 460 nm.

2D electrophoresis
Samples were loaded on isoelectric focusing gels (pH 3.0 to 10.0) (Novex, San Diego, CA). The
gels were run at 100 V for 1 hour and then at 200 V for 1 hour and 500 V for 30 minutes in an
XCM II Mini-Cell per company instructions (Novex, San Diego, CA). The gel was washed with
distilled water for 30 seconds and fixed and stained with Crocein Scarlet 7B (Sigma) and
Coomassie brilliant blue R-250 (Sigma) to determine the isoelectric point (pI) via the modified
Fairbanks protocol [112] with minor modification to incorporate fixation by Crocein Scarlet 7B.
Briefly, the proteins separated on IEF Gels were subjected to 2D electrophoresis using
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NuPAGE® 4-12% Bis-Tris Protein Gels with a 2D-well to separate focused proteins by mass
according to manufacturer specifications. The IEF gel was incubated in 100 mL 20% ethanol for
10 minutes, the desired lane cut out and incubated for 3-5 minutes in 1) 2 mL 2X SDS sample
buffer and 0.5 mL ethanol, 2) 0.25% 2-Mercaptoethanol βME in 1X sample buffer, and 3) 125
mM Alkylating Solution consisting of iodoacetamide in 1X sample buffer. Each incubation step
was followed by rinsing with 1X NuPAGE® MES SDS Running Buffer. The IEF gel strip was
transferred into the 2D well of the NuPAGE gel and run at 200V. A pre-stained low MW marker
(Bio-Rad 161-0305) was used.

Results:
Purification of recombinant human αGal in P. pastoris
αGal was obtained from a 7 L bioreactor (Figure 3-5) and purified (Table 3-1, Figure 3-6) using
the DEAE and Thio-Gal columns. Due to the high concentration and volume of enzyme needed
for the uptake studies planned, the more efficient DEAE column was substituted for the Con A
Sepharose 4B (GE Healthcare No. 17-0440-01) column used in earlier experiments. The ConA
column required lengthy soaks which caused a loss of enzyme. The DEAE column however, has
much greater efficiency, being much quicker, and results in over 80% recovery of sample. Sideby-side comparison of the two procedures showed they both result in pure enzyme being
produced, observed in specific activity and on SDS-PAGE.
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Figure 3-5: Fermentation profile of the bioreactor expression of recombinant
human αGal in pichia following a methanol-limited strategy.
The fermentation process is divided in 3 major stages. The initial glycerol batch and
fed-batch, are intended to achieve a high cell concentration. Once the desired cell
concentration is achieved (approximately hour 48), the methanol fed-batch phase
starts triggering αGal production. During the whole process, enough aeration is
guaranteed to maintain a dissolved oxygen set-point above 40%, keeping glycerol and
then methanol as the limiting nutrients. Bioreactor run terminated when a drop in
enzyme activity is observed.

The non-glycosylated monomeric form of αGal is 41.8 kDa. However, the form isolated from
cells contains multiple glycosylated species with a predominant band of about 50 kDa and
multiple higher molecular weight forms that differ in extent of glycosylation (Figure 3-6). We
have previously demonstrated that high molecular weight glycoforms produced in insect cells
and P. pastoris can be identified as derivatives of αGal rather than contaminants and these
glycoforms are converted to a single band on SDS gels of about 41.8 kDa with endoglycosidase
treatment [7-9, 20] and all appear in a western blot [20].
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Figure 3-6: αGal was purified as a single
band on an SDS-PAGE gel.
Purified samples were run on a 4–20%
polyacrylamide gel, under reducing conditions,
and stained with Coomassie Brilliant Blue. The
contents of the lanes are as follows: Bio-Rad
unstained low molecular weight ladder (lane 1),
Supernatant (lane 2), DEAE pool (lane 3), and
Thiogal pool (lane 4). The minor bands present
in the purified fraction are consistent with high
molecular weight glycoforms seen previously
when WT enzyme was purified from the
same P. pastoris expression system. [7] [20]

Table 3-1: Purification Table for αGal Expressed in P. pastoris
Step

Total Protein
(mg)

Total Activity
(Units ´ 106 )

Supernatant

55,550

208

3.7

1.0

100

DEAE Pool

653

137

211

56.2

66.0

Thio-Gal Pool

9.92

25.0

2,504

668

11.9
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Uptake of αGal using confocal microscopy
Confocal microscopy was used as a reliable and sensitive method of monitoring uptake of αGal
(Figure 3-7, 3-8, 3-12). The recombinant αGal was tagged with Alexa 488 according to
manufacturer specifications. Initial experiments showed that uptake could be accurately
monitored in both IMFE1 and FFB cells after fixation for short time periods as well as overnight
(Figure 3-7, 3-8, 3-13). Untagged recombinant αGal was used as a negative control to account
for auto-fluorescence. In these experiments, LysoTracker Red DND-99 was used to identify
lysosomes allowing for monitoring uptake as well as co-localization/ targeting to the lysosomes
of αGal (Figure 3-7, 3-8, 3-12). The nuclear stain DAPI was also used to visualize the nucleus.
In addition to 2D confocal images (Figure 3-8), 3D images using z-stacks were generated in a
Zeiss LSM 710 Confocal microscope to better visualize co-localization of αGal with the
lysosomes (Figure 3-7).
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Figure 3-7: Uptake of αGal-Alexa using 3D confocal microscopy.
Laser-scanning microscope 3D images of uptake of αGal-Alexa in normal fibroblast cells.
Cells are labeled with LysoTracker Red (red) to identify lysosomes, DAPI nuclear stain
(blue) and αGal with AlexaFluor488 fluorescent tag (green; yellow represents colocalization) from a LSM 710 Super-Resolution confocal laser-scanning microscope.

ALEXA

LysoTracker Red

DAPI

Co-localization

αGal
(no Alexa)
(- Control)

αGalAlexa

Figure 3-8: Uptake of αGal-Alexa in fixed cells using normal fibroblast (NFB) cells (2hr incubation).
αGal-Alexa (5 ug/ml) was added to wells containing NFB cells and incubated for 2-hour at 37˚C and 5% CO2.
Cells were fixed post incubation with Alexa tagged αGal and counterstained with LysoTracker Red DND-99 for
co-localization analysis. Post fixation the cells were covered with the ProLong® Diamond Antifade Mountant
with DAPI before imaging on a LSM 710 confocal laser-scanning microscope.
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Live cell imaging
Live cell imaging provides for continuous monitoring of uptake compared to images acquired in
fixed cell confocal experiments. We carried out live cell imaging over an 80-minute time period
(Figure 3-9). For this live cell assay a ZEISS LSM 880 Super-Resolution confocal laser-scanning
microscope with Airyscan and live cell temperature and CO2 incubator attachment was used.
Cells were incubated with αGal-Alexa in FluoroBrite™ DMEM and Prolong Live Antifade
Reagent in the presence of 5 mg/ml BSA to increase enzyme stability. By monitoring uptake in
one cell over a period of time we hoped to be able to draw conclusions as to the dynamics of
uptake in that cell and could potentially use this as a means to compare uptake of our sample preand post aconitylation.
We initially observed excessive bleed through of LysoTracker Red into the green Alexa
(490/525) channel during preliminary live cell experiments, which made accurate quantification
of the green channel impossible. To resolve this issue LysoTracker Deep Red (647 ⁄ 668) was
substituted for the more commonly used LysoTracker Red (577⁄590) marker to identify
lysosomes. We also observed bleed through of the live cell nuclear stain, Hoechst 33342
(360⁄460) into the green Alexa (490/525) channel. We were unable to resolve this issue and
therefore omitted the nuclear dye from our live cell experiments to maintain the integrity of the
quantification of the green channel (Figure 3-9).
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30 min

40 min

50 min

60 min

70 min

80 min

Figure 3-9: Uptake of αGal-Alexa using live cells.
αGal-Alexa (5ug/ml) was incubated in Fabry fibroblast in the live cell attachment of a ZEISS
LSM 880 confocal microscope at 37˚C and 5% CO2. Images were acquired every 10 minutes.
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ImageJ was used to quantify the uptake of the Alexa tagged enzyme in confocal studies as
described in the methods (Figures 3-10). N=5 cells were initially chosen at random (more cells
would need to be imaged to draw substantial conclusions in future studies) and the images from
this live experiment were analyzed and uptake quantified with ImageJ (Figure 3-11). ImageJ
allows quantification of an otherwise subjective data set. It also identifies the existence of the

Figure 3-10: Quantification procedure of confocal images with ImageJ.
a) Particle analysis of the LysoTracker (red) channel in ImageJ identifies lysosome particles, b)
Particle analysis of the Alexa-488 (green) channel in ImageJ identifies enzyme particles c) Colocalized image generated by ImageJ. d) zoomed in view showing co-localized particles e) zoomed in
view showing co-localization in original confocal image. f) Particle analysis in ImageJ on colocalized image identified co-localized particles. g) Zoomed in view showing numbered co-localized
particles.
cell-to-cell variability consistent with variations seen when measuring uptake by fixed cell
confocal microscopy.
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Quantification of uptake in n = 5 cells (Figure 3-11), highlights the dramatic cell to cell
variability initially observed in fixed cell experiments but allows us to still observe the general
trend in the increase of uptake of Alexa tagged αGal over the 80-minute incubation period. In
future studies flow cytometry can be used to address this cell to cell variability. By using flow
cytometry to monitor the presence of the Alexa tagged enzyme we would be able to analyze
millions of cells and therefore draw more concreate conclusions as to the trends observed. The
dip in uptake observed at 80 minutes is due to a shift in focus of the LSM 880 lens from the
optimal position do to repeated plate movements necessary to visualize all selected cells.

Figure 3-11: Particle analysis of live cell uptake of αGal-Alexa in Fabry fibroblast (FFB)
cells.
αGal-Alexa (5ug/ml) was incubated in FFB cells in the live cell attachment of a LSM880
confocal microscope. Distinct fields/cells (n=5) were chosen for continued analysis and confocal
images of these fields were acquired every 10 minutes. Uptake was quantified using ImageJ.
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Time course confocal microscopy in fixed cells using IMFE1 endothelial cells
Uptake of αGal was monitored in IMFE1 immortalized endothelial cells over different time
periods; 0, 0.5, 2 and 19 hours (Figure 3-12). Cells were incubated with enzyme for the indicated
time periods and then fixed before imaging in a confocal microscope. An average of 15 cells was
imaged in each instance and the images analyzed using ImageJ (Figure 3-13). These results
indicated an increase in both uptake of αGal-Alexa as well as co-localization of the enzyme with
the lysosomes over time. Untagged recombinant αGal was used as a negative control to account
for auto-fluorescence.
This time course analysis (Figure 3-13) indicates that αGal is initially taken up at a higher rate (t
<3hrs) and that uptake plateaus with longer incubation times (19 hours). These trends were
confirmed in uptake studies done where enzyme assay was used to quantify uptake in both FFB
and IMFE1 cells (Figure 3-17).
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Figure 3-12: Time course uptake of αGal-Alexa in IMFE1 cells.
αGal-Alexa (5 ug/ml) in IMFE cells post 0.5, 2, and 19-hour incubation at 37˚C and 5% CO2. Cells were
incubated with Alexa tagged αGal and counterstained with LysoTracker Red DND-99 for 2 hours before
fixation for co-localization analysis. Post fixation the cells were covered with the ProLong® Diamond Antifade
Mountant with DAPI before imaging on a LSM 710 confocal laser-scanning microscope.
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Figure 3-13: Particle analysis of uptake of αGal-Alexa in IMFE1 cells from (Figure 3-12).
Quantification with ImageJ of uptake and co-localization with lysosomes of αGal-Alexa (5 ug/ml)
in IMFE1 cells post 0.5, 2, and 19-hour incubation at 37˚C and 5% CO2. (mean and standard
deviation from n=15 cells)

74

Mariam Meghdari

Uptake of αGal is dose dependent
It has been previously reported that FFB in cell culture take up the recombinant human αGal
produced in insect cells and P. pastoris in a dose dependent manor as measured using direct
enzyme assays (Figure 3-14) [7-9].

Figure 3-14: Purified recombinant αGal produced in insect
cells and P. pastoris is taken up by FFB (GM2775) in cell
culture [7-9].

Uptake of the recombinant human αGal produced in the 7L bioreactor and purified using the
DEAE and Thio-Gal columns was measured by direct enzyme assay in FFB and IMFE1 cells in
replicates and was confirmed to be dose dependent in an overnight incubation with enzyme
(Figure 3-15).
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Normal Enzyme Level

Normal Enzyme Level

Figure 3-15: Dose dependent uptake of αGal in Fabry fibroblast (FFB) and Fabry
endothelial (IMFE1) cells.
Cells were incubated with indicated doses of αGal overnight (19 hours) in replicates, then
lysed and uptake was quantified using enzyme assay with the artificial substrate MUG as
described in the methods.
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Recombinant αGal produced in Pichia is taken up in higher levels in Fabry
endothelial cells (IMFE1) compared to Fabry fibroblasts (FFB)
In a recent study analyzing the lysosomal delivery of the available therapeutic αGal in
cell models of Fabry disease, it was shown that total endothelial uptake was less than fibroblast
uptake at concentrations relevant to the therapeutic situation (≤ 3 µg/ml) (Figure 3-16B) [15].
This is in accord with the currently approved ERT being mediated by the M6P receptors which
are generally absent from endothelial cells, a major site of GB3 accumulation in Fabry disease.

A) Recombinant Pichia αGal
(Meghdari, unpublished)

B) Therapeutic
(Replagal or Fabrazyme) [15]

Figure 3-16: Comparison of uptake trends of αGal produced in pichia and mammalian cells in
fibroblast and endothelial cells.
A) Recombinant αGal produced in Pichia was incubated with FFB and IMFE1 overnight at varying
concentrations. Uptake was quantified using direct enzyme assay. B) Uptake of αGal in normal
fibroblasts and blood outgrowth endothelial cells. Uptake after 3-hour incubation at varying enzyme
concentration of Replagal (Shire Human Genetic Therapies) or agalsidase beta - Fabrazyme (Genzyme
Corporation – a Sanofi subsidiary) [15].
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In order to investigate these results, the recombinant αGal was incubated overnight at varying
concentrations in Fabry fibroblast and endothelial cells (Figure 3-16A). Published results (Figure
3-16B) [15] indicate the current M6P terminated therapeutic is taken up in greater abundance in
FFB as opposed to endothelial cells. Our mannose terminated enzyme, rectifies this issue with
observed increased uptake in disease-relevant IMFE1 as opposed to FFB (Figure 3-16A). Our
Mannose terminated recombinant αGal was taken up at much higher levels in endothelial cells, a
major disease-relevant cell type in Fabry disease.

Uptake of αGal in IMFE1 cells reaches a plateau after 3 hours
To compare uptake rates in a dynamic phase, IMFE1 and FFB cells were incubated with
recombinant αGal overnight (19 hours) and for a shorter time period of 3 hours and uptake
quantified by enzyme assay (Figure 3-17). Uptake in IMFE1 cells was substantially higher than
FFB at both time points with maximum uptake being reached after 3-hours of incubation with
αGal. We hypothesize that this plateau is most likely due to saturation of uptake by the MR, in

Figure 3-17: Comparison of time course uptake of αGal in FFB and IMFE1 cells.
αGal was incubated with FFB and IMFE1 cells overnight and at 3hours at a concentration
of 6 µg/ml. Uptake was quantified using enzyme assay.
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which all accessible MR have bound enzyme. These results agree with trends observed in
Confocal studies (Figure 3-13) and indicate the need to monitor uptake at lower time points in
IMFE1 cells in order to study kinetics of uptake.

Preliminary control experiments to demonstrate aconitylation of HSA
HSA was aconitylated as per published methods with minor changes to accommodate αGal
instability at high pH (Figure 3-18) [165, 167, 176]. We synthesized Aco-HSA by reacting the
surface lysine residues of HSA in buffer at a pH of 7.5 with excess cis-aconitic anhydride and
stirring at 4°C for 1hr. The degree of modification of lysines was assessed by estimating the loss
of free amino groups as measured by TNBS [18] or fluorescamine [177] assay post removal of
excess anhydride and using a glycine standard curve (Table 3-2). In addition, the pre-and post
aconitylated samples were analyzed using native PAGE, isoelectric focusing (IEF), and 2D
isoelectric focusing to measure aconitylation. (Figure 3-19, 3-20).

Figure 3-18: Analysis of stability of αGal over high pH range.
Conjugation with cis-aconitic anhydride is recommended under basic
conditions (pH 8.5) [18]. In preliminary experiments, we measured the
stability of αGal at pH 6.5 to 8.5 at incubations times of 15, 30, and 60
min. The results indicated that conjugation at a pH of 7.5 for 30 or 60 min
was optimal to prepare Aco-αGal.
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Table 3-2: Overview of HSA/BSA aconitylation samples

Sample

Aco-HSA

Aco-BSA

conc. Anhydride
added

% Aconitylation
Fluorescamine

1X
1X

56
43

0.5X

52

2X
2X
1X
2X

61
52
36
42

A) native PAGE

B) Isoelectric focusing gel

Figure 3-19: Analysis of charge of HSA pre-and post aconitylation.
A) Native PAGE separates HSA/Aco-HSA samples based on size to charge ratio
and B) IEF gel separates HSA/Aco-HSA samples solely based on their charge.
The more negatively charged Aco-HSA samples migrates farther on both gels
confirming aconitylation of the sample.
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A) HSA

B) Aco-HSA

Figure 3-20: 2D electrophoresis of HSA and Aco-HSA samples.
Appropriate lanes were cut out of IEF gels and after preparation (see methods) loaded on the 2D well
of an SDS-PAGE gel.

Aconitylation promotes uptake of HSA
It was reported in the literature that the introduction of negative charges on the surface of
proteins by chemical modifications such as acetylation or aconitylation targets proteins for
uptake by the scavenger receptor family of integral membrane proteins [4, 167]. Specifically,
aconitylation of HSA was reported to result in massive uptake in vivo and in vitro to the
lysosomes of endothelial cells [164, 178]. An essential step in enzyme therapy for Fabry disease
and other lysosomal storage diseases depends upon enzyme uptake and lysosomal transport by
multiple cell types and using several uptake pathways. HSA has a circulating half-life of 20 days
due to its size and protection from intracellular degradation in the lysosome, making it a good
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control for the aconitylation experiments with αGal. In preliminary experiments, we modified
HSA by aconitylation and tagged it with the fluorescent dye Alexa488 and monitored uptake into
normal human fibroblast cells using confocal microscopy (Figure 3-21).
No detectable fluorescence of Alexa488 (green fluorescence) was detected in a control
experiment for lysosomes (labeled with LysoTracker Red) with unmodified and unlabeled HSA
(Figure 3-21A, Frames 1, 2) and very low levels of uptake were detected with unmodified HSAAlexa488 (Figure 3-21B, Frames 1,2). In contrast, significant accumulation of Aco-HSAAlexa488 was detected in lysosomes as indicated by co-localization of LysoTracker Red (red
fluorescence) with Alexa488 (green fluorescence) in the formation of yellow lysosomal
compartments (Figure 3-21C, Frames 1,2,3,4). These results confirm literature reports that AcoHSA is successfully targeted to the lysosome and demonstrate the efficacy of our aconitylation
protocol.
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(A)

(B)

(C)

(D)
HSA-Alexa
(Frame 1 channels)

LysoTracker
Red

Alexa

DAPI

Co-localized

DAPI

Co-localized

(E)
Aco-HSA-Alexa
(Frame 1 channels)

LysoTracker
Red

Alexa

Figure 3-21: Uptake of HSA-Alexa compared to Aco-HSA-Alexa in NFB.
Cells were labeled with LysoTracker (red) to identify lysosomes, DAPI nuclear stain (blue)
Cells were incubated for 3 hours with A) HSA (Control) B) HSA and C) Aco-HSA with
AlexaFluor488 fluorescent tag (Green); yellow represents co-localization) from a LSM 710
Super-Resolution confocal laser-scanning microscope. Multiple frames shown for
clarification. D) Individual channels of Frame 1, cells incubated with HSA-Alexa E)
Individual channels of Frame 1, cells incubated with Aco-HSA-Alexa.
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Aconitylation of HSA targets the enzyme to the scavenger receptor uptake
pathway
U2OS-SRA cells are human U2OS osteosarcoma cells over-expressing the murine scavenger
receptor A. Because of the dramatic increase of scavenger receptors present in these cells in
contrast to their control (U2OS cells) they are used as a tool for identifying uptake to the
scavenger receptor uptake pathway [179].
Confocal uptake studies were done with Aco-HSA in U2OS cells as well as U2OS-SRA cells
overexpressing scavenger receptor type A. Aco-HSA was taken up more readily in U2OS-SRA
cells than in U2OS cells after a short incubation time of 2 hours. This difference practically
disappears after overnight incubation with the fluorescently labeled Aco-HSA when uptake
seems to plateau in both cells types (Figure 3-22).
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A) 2hr incubation

Cells

Aco-HSA-Alexa

LysoTracker Red

DAPI

Co-localization

LysoTracker Red

DAPI

Co-localization

U2OS

U2OS-SRA

B) Overnight incubation

Cells

Aco-HSA-Alexa

U2OS

U2OS-SRA

Figure 3-22: Uptake of Aco-HSA-Alexa in U2OS and U2OS-SRA cells.
Aco-HSA-Alexa (5 ug/ml) in U2OS and U2OS-SRA cells A) post 2-hour incubation and B) post overnight
incubation at 37˚C and 5% CO2. Cells were incubated with Alexa tagged αGal and counterstained with
LysoTracker Red DND-99 for 2 hours before fixation for co-localization analysis. Post fixation the cells were
covered with the ProLong® Diamond Antifade Mountant with DAPI before imaging on a LSM 710 confocal
laser-scanning microscope.
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Aconitylation of αGal
The first step in forming SR-targeted αGal is to construct aconitylated and fluorescently-labeled
αGal. αGal has 33 lysines per subunit; the programs ASA-View [180] and GetArea[181] were
used to visualize and analyze the relative surface accessibility of residues of the Protein data
bank (PDB) structure of human αGal (1R46)[10]. Relative solvent accessibility was determined
by dividing the accessible surface area of a residue for the maximum exposed surface of the
same residue type in a Gly–X–Gly oligopeptide, residues with relative solvent accessibility of
more than 50 % are considered to be solvent exposed. Using this calculation αGal contains
approximately 20 surface lysines in the monomer, which will be used for aconitylation and
fluorescent labeling (Figure 3-23). Cis-aconitic anhydride coupling to lysine residues introduces
a net three negative charges for each lysine residue (Figure 3-2).

Figure 3-23: Surface Lys residues of
αGal.
The surface structure of the αGal dimer
contains about 20 well-exposed Lys
residues (red). Aconitylation of ε-NH2
groups (Figure 3-2) introduces a net three
negative charges for each Lys residue.
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Aconitylation of αGal targets the enzyme to the scavenger receptor uptake
pathway in U2OS-SRA cells
Uptake of αGal and Aco-αGal was analyzed in U2OS cells (human bone osteosarcoma) as well
as U2OS-SRA cells (overexpressing murine scavenger receptor type A). Aco-αGal was more
readily taken up in U2OS-SRA cells with an average of 100 ± 74 particles of Aco-αGal-Alexa
per field than in U2OS cells with an average of 12 ± 9 particles of Aco-αGal-Alexa per field
after an incubation time of 2 hours with enzyme (Figure 3-24, 3-25, Table 3-3). This is similar to
the trend seen in the control with Aco-HSA (Figure 3-22). This is in contrast to the trend in
uptake of non-Aco-αGal in which uptake is similar in both cell types with slightly more uptake
being observed in U2OS-SRA cells indicating that non-Aco-αGal may also be slightly targeted
to the SR uptake pathway (159 ± 104 in U2OS vs 192 ± 20 in U2OS-SRA).
It is important to note that the overall uptake of non-Aco-αGal is higher than Aco-αGal in both
of these cells types. This is most likely due to the loss of approximately 44% in specific activity
of the enzyme during the aconitylation procedure. We also hypothesis that aconitylation may be
blocking another uptake pathway of non-Aco-αGal in U2OS cells but this hypothesis needs to be
tested further.
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Cells

αGal-Alexa

LysoTracker Red

DAPI

Co-localization

Aco- αGal -Alexa

LysoTracker Red

DAPI

Co-localization

U2OS

U2OSSRA

Cells

U2OS

U2OSSRA

Figure 3-24:Uptake of αGal-Alexa and Aco-αGal-Alexa in U2OS and U2OS-SRA cells.
U2OS and U2OS-SRA cells were incubated with Alexa tagged αGal-Alexa and Aco-αGal-Alexa at 37˚C and
5% CO2 for 2 hours. Cells were counterstained with LysoTracker Red DND-99 for 2 hours before fixation for
co-localization analysis. Post fixation the cells were covered with the ProLong® Diamond Antifade Mountant
with DAPI before imaging on a LSM 710 confocal laser-scanning microscope.
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A) Average particles per field for cells incubated with αGal-Alexa

B) Average particles per field for cells incubated with Aco-αGal-Alexa

Figure 3-25: Quantification of uptake of αGal-Alexa and Aco-αGal-Alexa in U2OS and U2OSSRA cells from Figure 3-24.
Confocal images were analyzed using ImageJ. A) cells incubated with αGal-Alexa, B) cells incubated
with Aco-αGal-Alexa. Values included in table are average particles per Field for n = 20 cells
imaged.
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Table 3-3: ImageJ particle analysis of Aco (+, -) αGal in U2OS and U2OS-SRA cells from
Figure 3-24.

Average # of particles per filed
Aco

+

-

Cells

U2OS

U2OS-SRA

U2OS

U2OS-SRA

Alexa

12 ± 9

100 ± 74

159 ± 159

192 ±20

192 ± 20

217 ± 96

185 ± 31

45 ± 14

66 ± 52

109 ± 18

LysoTracker 159 ± 104
Co-localized

8±7

Note. Values included in table are average particles per Field (n = 20 cells imaged).

In order to confirm targeting of Aco-αGal to the SR in U2OS-SRA cells, uptake was analyzed in
the presence and absence of the SR inhibitor PolyI (Figure 3-26). This experiment showed that
addition of PolyI completely inhibited uptake of Aco-αGal-Alexa in U2OS-SRA cells with no
green fluorescence being detectable in the presence of the inhibitor after a 2-hour incubation
(Figure 3-26B). This inhibition indicates that the primary pathway of uptake of Aco-αGal-Alexa
in these cells is through the scavenger receptor uptake pathway.
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A) Confocal Image of representative field
Inhibitor

Aco-αGal-Alexa

LysoTracker Red

DAPI

Co-localization

- PolyI

+PolyI

B) ImageJ particle analysis of all fields

Alexa
PolyI

-

+

Average
Per Field

30 ± 26

0

LysoTracker
+
172 ± 72

89 ± 26

Co-localized
+
22 ± 23

0

Figure 3-26: Uptake of Aco-αGal-Alexa in U2OS-SRA cells (+, -) PolyI inhibition.
Aco-αGal-Alexa was incubated in U2OS-SRA cells for 2 hour with and without 100 µg/ml PolyI at 37˚C and
5% CO2. Cells were counterstained with LysoTracker Red DND-99 for 2 hours before fixation for colocalization analysis. A) Representative image taken with a ZEISS LSM 880 confocal laser-scanning
microscope B) ImageJ particle analysis of all fields, mean and Standard deviation for n = 30-35 cells.
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αGal is targeted to the scavenger receptor uptake pathway in U2OS-SRA cells
Uptake of Alexa488 tagged recombinant αGal was monitored in U2OS-SRA cells as a control.
U2OS-SRA cells are human U2OS osteosarcoma cells over-expressing the murine scavenger
receptor, making them an ideal candidate for analyzing targeting to the scavenger receptors.
αGal-Alexa was incubated for two hours with cells with and without the scavenger receptor
inhibitor PolyI. Images were acquired of approximately 20 cells per well and analyzed. (Figure
3-27) Interestingly the addition of PolyI to the wells seems to have completely inhibited uptake
of the recombinant αGal in this cell type. This suggests that the enzyme produced in P. pastoris
may already be targeting to the scavenger receptor to some extent.

Inhibitor

αGal-Alexa

LysoTracker Red

DAPI

Co-localization

-PolyI

+PolyI

Figure 3-27:Uptake of αGal-Alexa in U2OS-SRA cells: Representative images.
Uptake of αGal-Alexa (5 ug/ml) in U2OS-SRA cells post 2 hour incubation at 37˚C and 5% CO2. Cells were
incubated with Alexa tagged αGal and counterstained with LysoTracker Red DND-99 for 2 hours before
fixation for co-localization analysis. Post fixation the cells were covered with the ProLong® Diamond
Antifade Mountant with DAPI before imaging on a LSM 710 confocal laser-scanning microscope.
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Aconitylation improves targeting of αGal to lysosomes in IMFE1 endothelial
cells
In order to compare the uptake and targeting to the lysosomes of aconitylated and non
aconitylated αGal in IMFE1 endothelial cells, a time course uptake study was done using AcoαGal-Alexa (Figure 3-28) to mimic what was done with non-Aco-αGal (Figure 3-12).
Incubation

Aco-αGal-Alexa

LysoTracker Red

DAPI

Co-localization

0.5 hr

2hr

19hr

Figure 3-28: Time course uptake of Aco-αGal-Alexa in IMFE1 cells.
Aco-αGal-Alexa (5 ug/ml) in IMFE1 cells post 0.5, 2, and 19-hour incubation at 37˚C and 5% CO2. Cells were
counterstained with LysoTracker Red DND-99 for 2 hours before fixation for co-localization analysis and
images taken on a LSM 710 confocal laser-scanning microscope.
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Table 3-4: ImageJ particle analysis of Aco (+, -) αGal time course uptake in IMFE1 cells.
Average # of particles per filed
Aco

+

-

Incubation
(hr)

0.5

Alexa

18 ± 3

24 ± 29 96 ± 45 10 ± 10 73 ± 27 110 ± 35

Co-localized

4±5

10 ± 20 50 ± 30

2

19

0.5

6±8

2

19

17 ± 19

42 ± 13

% Co-localized* 22 ± 27 36 ± 32 50 ± 18 58 ± 43 24 ± 23

41 ± 13

Note. Values included in table are average particles per field (n = 15-20 cells imaged).
*% Co-localized =

"#$%#&'%()*+
,%*-'

× 100

Initial time course analysis with αGal (Figure 3-13, 3-29A) indicates that αGal is initially taken
up at a higher rate (t <3hrs) and that uptake plateaus with longer incubation times (19-hours) in
IMFE1 cells. In the case of Aco-αGal however this relationship seems to be more linear with
uptake increasing steadily over time (Figure 3-29B). Compression of the uptake of aconitylated
and non-aconitylated αGal shows that at t = 0.5 hours, Aco-αGal is taken up better (18 ± 3 Alexa
particles) than non-Aco-αGal (10 ± 10 Alexa particles) in IMFE1cells with the difference being
close to 4-fold once the ~50% loss in specific activity of the aconitylated sample is taken into
account.
Comparing the amount of Aco (+, -) αGal co-localized with the lysosomes, we see that a higher
percentage of internalized enzyme are targeted to the lysosomes (% co-localized) in the case of
Aco-αGal with this percentage steadily increasing with the increase of overall uptake over the
three time points measured (22% ® 36% ® 50%). In contrast, the growth of % co-localization
seems to be much slower in non-Aco-αGal (58% ® 24% ® 41%) (Table 3-4).
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A) Uptake of αGal-Alexa in IMFE1 cells

B) Uptake of Aco-αGal-Alexa in IMFE1 cells

Figure 3-29: Particle analysis of time course uptake of Aco-αGal-Alexa in IMFE1 cells from
Figure (3-13, 3-28).
A) αGal-Alexa (5 ug/ml) B) Aco-αGal-Alexa (5 ug/ml) in IMFE1 cells post 0.5, 2, and 19-hour
incubation at 37˚C and 5% CO2. Uptake was quantified using ImageJ as described in methods.
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αGal produced in Pichia is targeted to the mannose receptor
To further investigate potential receptors involved in the uptake of the aconitylated and nonaconitylated αGal produced in yeast, uptake of these enzymes was monitored in the presence of
M6P and Mannan and scavenger receptor inhibitors PolyI, Aco-HSA, and Ac-LDL in an
overnight uptake experiment (Figure 3-30A, 3-31A) by enzyme assay and with a combination of
Mannon and PolyI during a 2-hour incubation (Figure 3-30B, 3-31B) using confocal microscopy.
Our results indicated a reduction of approximately 80% in uptake overnight and approximately
40% after 2 hours when the MR is inhibited indicating that in IMFE1 cells this is the major
pathway for uptake of non-Aco-αGal (Figure 3-30).
SR inhibitors PolyI, Aco-HSA, and Ac-LDL had no effect on uptake of non-aconitylatd αGal in
IMFE1 cells (Figure 3-30). Therefore, despite our previouse results indicating αGal ability to
target to scavenger receptors (Figure 3-27), the scavenger receptor does not contribute very much
to the overall uptake of αGal uptake in IMFE1 cells. Unexpectedly, these inhibitors increased
uptake in the case of Aco-αGal both in overnight studies measured with enzyme assay (Figure 331A) as well as confocal studies where uptake was analyzed using imageJ (Figure 3-31B). The
reason for this increase in uptake when the scavenger receptor is inhibited is unknown but one
reason may be due to competition between the mannose and scavenger receptors for Aco-αGal.
This is further demonstrated when both receptors are inhibited (Figure 3-31B). In this case, the
uptake of Aco-αGal is decreased more than with mannan alone indicating both receptors are
playing a role in the uptake of Aco-αGal.
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A) Overnight (19 hours) incubation

B) 2-hour incubation

Average # of particles of Alexa per field
Inhibitor

No Inhibitor

Mannan

PolyI

Non-Aco-αGal

78 ± 27

46 ± 55

86 ± 41

Figure 3-30: Effect of inhibitors on uptake of non-Aco-αGal in IMFE1 cells.
A) αGal (6 µg/ml) were incubated overnight (19 hours) at 37˚C and 5% CO2 in IMFE1
cells post. The effect of 5mM M6P, 2 mg/ml Mannan, 10 µg/ml Aco-HSA, and 100 µg/ml
Poly(I) were tested in duplicate. Uptake was quantified using enzyme assay, B) Uptake of
αGal-Alexa (5 ug/ml) in IMFE1 cells post 2-hour incubation at 37˚C and 5% CO2. The
effect of 2 mg/ml Mannan and 100 µg/ml Poly(I) were tested. Uptake analyzed by confocal
microscopy. Results are displayed as % of control (No Inhibitor = 100%).
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A) Overnight (19 hours) incubation

B) 2-hour incubation

Average # of particles of Alexa per field
Inhibitor(s) No Inhibitor Mannan
Aco-αGal

56 ± 68

41 ± 69

PolyI

PolyI + Mannan

69 ± 55

20 ± 22

Figure 3-31: Effect of inhibitors on uptake of Aco-αGal in IMFE1 cells.
A) Aco-αGal (6 µg/ml) were incubated overnight (19 hours) at 37˚C and 5% CO2 in IMFE1
cells post. The effect of 5mM M6P, 2 mg/ml Mannan, 10 µg/ml Aco-HSA, and 100 µg/ml
Poly(I) were tested in duplicate. Uptake was quantified using enzyme assay, B) Uptake of
Aco-αGal-Alexa (5 ug/ml) in IMFE1 cells post 2-hour incubation at 37˚C and 5% CO2.
The effect of 2 mg/ml Mannan and 100 µg/ml Poly(I) were tested. Uptake analyzed by
confocal microscopy. Results are displayed as % of control (No Inhibitor = 100%).
98

Mariam Meghdari

Measurement of the degree of aconitylation of αGal
We synthesized Aconitylated αGal by reacting the ε-NH2 group of lysine residues of
approximately 1 mg/ml of purified αGal in Buffer A at a pH of 7.5 with excess cis-aconitic
anhydride (SIGMA) as preformed with the positive control HSA and described in literature [165,
167, 176]. The pH of the reaction mixture was adjusted to 7.5 post anhydride addition with 1M
NaOH and was then stirred at 4˚C for approximately 1.5 hours. Either dialysis or a Sephadex G25 column were used to remove excess anhydride.
The degree of modification of lysines was assessed by estimating the loss of free amino groups
and using a glycine standard curve as measured by TNBS assay [182] and the more sensitive
fluorescamine assay [113] post removal of excess anhydride. In addition, 2D electrophoresis was
done on the pre-and post aconitylated samples as described in the previous section for HSA
(Figure 3-19, 3-20).
Table 3-5: Overview of αGal aconitylation samples

Aco-αGal sample

Conc.
Anhydride
added

% Aconitylation
Fluorescamine

% Aconitylation
TNBS

MMII112

1X

NA

47

63.61

1X

-6

NA

63.66

1X

-5

NA

63.71

5X

-53

-183

63.73

2X

-15

NA

63.74

2X

-35

-378

63.83

2X

11

-32

60.28

2X

-20

NA

40.22 (Δ4)

2X

-16

NA
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Aconitylation was performed on multiple preparations of recombinant αGal. Initially it was
observed by TNBS assay that the αGal sample was successfully aconitylated (Table 3-5). These
aconitylated samples were tagged with Alexa488 and confocal studies were subsequently
performed. Upon further testing with the TNBS assay it was observed that there is large
variability between replicates in this assay with the signal being very low above background.
Therefore, the more sensitive fluorescamine assay was used to confirm aconitylation of samples.
This assay indicated that no aconitylation had taken place in either of the preparations (Table 35). Because of the puzzling nature of this result IEF was done on all aconitylated and nonaconitylated samples to clarify the issue.
IEF gels were run as described earlier, in all gels except for one, non-aconitylated αGal presented
as a broad band as opposed to a sharp band as we had anticipated indicating our recombinant
sample is present as a mixture containing varying negative charge (Figure 3-32A). There was no
difference observed in the native PAGE (3-32B) and IEF gels (Figure 3-32A) for aconitylated
and non-aconitylated αGal. When these bands were run on the second dimension SDS-PAGE it
further confirmed that this method could not be used to confirm aconitylation of our samples
(Figure 3-32C, 3-32D). This inability to confirm aconitylation using TNBS assay, fluorescamine
assay, and IEF gels conflicts with the results we see in confocal uptake studies with aconitylated
and non-aconitylated αGal.
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αGal

(C)

Aco-αGal

(B) native PAGE

Aco-αGal

αGal

(A) Isoelectric focusing gel

(D)

Figure 3-32: Gel electrophoresis of representative αGal and Aco- αGal samples.
A) IEF and B) Native PAGE were performed under non-denaturing conditions on
αGal and Aco-αGal samples. Lanes containing C) αGal and D) Aco-αGal were cut out
of the IEF gel and run on a NuPAGE® 4-12% Bis-Tris Protein Gels with a 2D-well to
separate focused proteins by mass according to manufacturer specifications.
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Discussion:
Our findings suggest that the recombinant αGal produced in P. pastoris is taken up by the MR
and by the SR uptake pathways and that aconitylation of αGal increases the uptake by the SR
resulting in better delivery of enzyme to lysosomes in Fabry endothelial cells. Our results also
confirm that aconitylation of HSA improves uptake and delivery to the lysosomes.
The two therapeutics currently available for ERT are expressed in Chinese Hamster Ovary
(CHO) cells used by Genzyme and HT1080 (fibroblasts derived from fibrosarcoma) used by
Shire. The use of these mammalian cell lines is due in part to their ability to perform human-like
glycosylation containing M6P, promoting uptake of the therapeutic by the M6P pathway. It was
initially assumed that targeting to the M6P pathway is necessary for ERT therapy in LSD such as
Fabry disease. However, more recent results indicate that mannose terminated forms of human
αGal produced in moss (moss-αGal) [1] as well as tobacco cells [70] (PRX-102, chemically
modified, resulting in a cross-linked dimer of PEGylated subunits increasing enzyme stability)
are taken up by different cells types and are successful in clearing substrate in both in-vitro and
in-vivo studies. Although the mechanism of uptake for PRX-102 is unknown, the mannose
terminated moss-αGal is shown to be taken up by the MR (Figure 3-33). Shen et. al. suggested
that mannose-terminated enzymes can be more effective than M6P terminated enzymes in the
treatment of Fabry disease, and that M6P residues may not always be a prerequisite for ERT as
previously assumed. These newly developed recombinant enzymes are among 122 other Fabry
disease therapies currently in clinical trials (ClinicalTrials.gov).
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A)

B)

Figure 3-33: Uptake of moss αGal [1].
A) Uptake rates of different enzymes in IMFE1 cells. Cells were harvested at indicated
time points and intracellular activities were measured. ***P < 0.001, moss-αGal vs. high
mannose (high-mann) moss-αGal or agalsidase alfa (current therapeutic). B) Intracellular
αGal activities of IMFE1 cells after overnight incubation with different enzymes in the
presence or absence of M6P or mannan.

Unlike mammalian glycosylation patterns which are phosphorylated and composed of sugars
terminated with sialic acid residues, enzymes produced in P. pastoris contain a simpler form of
glycan known as high mannose (Figure 3 34). These glycans are composed of two core Nacetylglucosamine residues and ramified mannoses (Figure 3-34) The MR has been shown to be
present on endothelial cells [1] a major site of accumulation of GB3 in Fabry disease. Our results
show that our recombinant high mannose αGal produced in P. pastoris is mainly targeting the
MR as indicated by a reduction of approximately 80% in uptake overnight and approximately
40% after 2 hours of incubation in the presence of mannan (Figure 3-29). We also show that
αGal expressed in P. pastoris is taken up more readily in immortalized Fabry endothelial cells
(IMFE1) than in Fabry fibroblast cells (Figure 3-16A) which contain low levels of MR[1].
Published results indict the therapeutic αGal with M6P regulated uptake is more efficient in
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fibroblast than endothelial cells (Figure 3-16B). This better delivery to endothelial cells could
prove to be tremendously advantageous in ERT in both Fabry disease and other LSDs.

Figure 3-34: Types of N-glycans.
The three different types (High Mannose, Complex and Hybrid) share a common core
structure including the first two N-acetylglucosamine residues and the first three mannose
residues.[11]

SRs are a diverse group comprised of membrane proteins and soluble secreted extracellular
domain isoforms with the ability to recognize common ligands such as poly-ionic ligands
including lipoproteins, apoptotic cells, cholesterol esters, phospholipids, proteoglycans, ferritin,
and carbohydrates. SRs are grouped into subclasses with little to no primary sequence similarity
between each class. HSA was aconitylated and the change in charge of the protein was
confirmed by TNBS Assay as well as isoelectric focusing gels (Figure 3-19, 3-20). This
negatively charged Aco-HSA was fluorescently tagged with Alexa 488 and was shown to target
more readily than non-Aco-HSA to the lysosomes in NFB cells, using confocal microscopy
(Figure 3-21). In addition, confocal studies in U2OS as well as U2OS-SRA cells showed that
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aconitylated HSA is taken up more readily in U2OS-SRA cells than in U2OS cells after a short
incubation time of 2 hours. This difference is narrowed after overnight incubation where uptake
seems to plateau in both cells types (Figure 3-22). U2OS cells contain low levels of the type A
scavenger receptor SRABA5 [183], this may be the reason we are able to see uptake of AcoHSA in U2OS cells overnight.
Mimicking trends seen in the HSA control, aconitylation of αGal also resulted in targeting of the
enzyme to the scavenger receptor as demonstrated by complete inhibition of uptake in U2OSSRA cells post incubation with the scavenger receptor inhibitor PolyI (Figure 3-26).
Interestingly, non-Aco-αGal was also shown to have the potential to target to the scavenger
receptor uptake pathway (Figure 3-27). αGal is a negatively charged enzyme (Figure 3-35)
which is most likely why it is targeted to the scavenger receptors in this cell type. This is

Figure 3-35: Surface potential of αGal.
Image generated in Chimera.
however not the major uptake pathway in the more therapeutically relevant IMFE1 cells.
Inhibition studies done overnight and analyzed using enzyme assay as well as with 2-hour
105

Mariam Meghdari

incubation (analyzed using confocal microscopy) in IMFE1 cells, revealed that Poly I had no
major effect on uptake of non-Aco-αGal in these cells (Figure 3-30). In contrast, addition of SR
inhibitors such as PolyI, Aco-HSA, and Ac-LDL cause an increase in uptake of Aco-αGal in
IMFE1 cells (Figure 3-31). Our results indicate that in the case of Aco-αGal the mannose and
scavenger receptor uptake pathways compete for internalization of Aco-αGal with the MR
resulting in more efficient internalization into the cell while the SR results in faster targeting to
the lysosomes.
Further analysis with our αGal sample using confocal uptake studies done on live cells (Figure 39, 3-11) and time course studies in fixed cells (Figure 3-12, 3-13, 3-17) indicate that uptake in
IMFE1 cells is initially rapid at t < 3 hours and plateaus with a longer incubation time of 19
hours (Figure 3-13, 3-17). This is in contrast to general trends observed with Aco-αGal in which
overall uptake as well as percentage of internalized enzyme targeted to the lysosomes (% colocalized) increases steadily over a period of 19 hours (Figure 3-28B) (Table 3-4). This steady
increase indicates the potential of Aco-αGal as an
improved form of therapy and should therefore be
further analyzed in longer experiments in vitro as well
as in vivo.
In contrast to HSA we were unable to confirm
successful aconitylation of our recombinant αGal.
TNBS and fluorescamine assays had varying results
with variable preparations and were consistently
inconclusive with the number of free surface lysines
being identified post aconitylation being higher than
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Figure 3-36: Isoelectric focusing gel
of Fabrazyme and Replagal. [3]
Lane 1, Pharmacia IEF standards, pH
2.5±6.5; lane 2, 10 m g Fabrazyme;
lane 3, 10 m g Replagal.
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pre aconitylation. In addition, IEF gels showed no difference between the aconitylated and nonAco-αGal samples (Figure 3-32A). Both of these samples appeared as a broad band or as a set of
bands in the pH range of 4-5. This result poses questions of its own as one would expect the nonaconitylated αGal sample to appear as a single band on an IEF gel. The therapeutics currently
being produced in mammalian cells appear to be similar on an IEF gel to the gels performed in
this lab (Figure 3-32A) [3]. This is consistent with αGal being produced in mammalian cells
containing negatively charged carbohydrates with M6P and sialic acid components accounting
for the lower pH range and the variability in charge seen on published IEF gels (Figure 3-36, 337) [19]. Further studies with our recombinant αGal are needed to analyze the reason for the
pattern we see on our IEF gels. It is unclear how high mannose glycans would have any effect on
the recombinant protein charge. Another explanation for the multiple charged proteins observed
could be protein deamidation which may occur during the purification process.

Figure 3-37: Comparison of the sizes and charges of
agalsidase beta [19].
(A) Sizes of agalsidase beta (Fbz; Fabrazyme) were
compared in SDS-PAGE before and after
deglycosylation using PNGase F digestion. Here, M
represents the molecular weight marker. (B) Isoelectric
patterns were analyzed in IEF gel with/without a
sialidase treatment.
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The inability to show aconitylation αGal could also be due to the fact that αGal contains only
approximately 20 exposed surface lysines while HSA contains about 60 lysines with most of
them having well-exposed lysine –NH groups making it possible to produce strongly negatively
charged poly-anionic molecules by reaction with cis aconitic anhydride.
The argument can therefore be made that the current available therapeutic for ERT, which due to
the presence of M6P and sialic acid residues is more negatively charged than the recombinant
αGal produced here, may also be targeted to the scavenger receptor uptake pathway to some

Figure 3-38: Comparison of the association of M6P-HSA liposomes and
AcoHSA liposomes [5].
Liver endothelial cells were incubated with [3H]cholesteryloleyl ether (3H-COE)
labelled M6P-HSA liposomes (closed bars) and AcoHSA liposomes (open bars) in
the absence or presence of 0.1 mg/ml M6P-HSA, AcoHSA or 10 mg/ml
polyinosinic acid. The association of M6P-HSA liposomes and AcoHSA
liposomes without treatment was taken as 100%. mean±SEM of 3–4 experiments.
**P<0.001 versus M6P-HSA liposomes without treatment, #P<0.05, ##P<0.001
versus AcoHSA liposomes without treatment.
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extent. These results corroborate published data suggesting that coupling M6P-HSA to liposomes
targets them to both the M6P and scavenger receptor uptake pathways in hepatic stellate and
endothelial cells (Figure 3-38) [5]. Therefore, enhancing the negative charge on αGal should
increase this targeting and result in a more efficient enzyme for ERT.

Conclusions:
Our overall results indicate the potential for the development of a therapeutic produced in Pichia
allowing for targeting to the MR with an increase in negative charge resulting in better
internalization to the lysosomes by targeting to the SRs. The aconitylation procedure results in
the loss of approximately 50 % in specific activity of αGal and therefore is not ideal for the
addition of negative charge. One possible solution to adding more negative charge to αGal is to
construct multi-arm–PEG-αGal-Aco-HSA conjugates, and liposomes encapsulating αGal with
surface Aco-HSA-targeting (Figure 3-39) Further studies involving construction of these
conjugates and multi-molecular assemblies composed of recombinant human αGal and
aconitylated HSA should be evaluated for targeting αGal to the SR uptake system without the
loss in specific activity seen with aconitylation, offering the potential for a better enzyme for
ERT.

Figure 3-39: Proposed α-Gal A Conjugates.
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